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 Opioid use disorder (OUD) is a chronic condition that affects three million people in the 
United States and 16 million people worldwide.  Randomized controlled trials (RCTs) are the 
gold standard for OUD, but there are multiple methodological complexities present in the 
analysis of randomized controlled OUD trials.  This dissertation applies novel and advanced 
biostatistical methods to the analysis of OUD RCTs, with the ultimate goal of improving future 
research in substance abuse RCTs. 
 Randomization is a key component of an RCT but high attrition and/or an inability to 
establish treatment therapy can pose a threat to its validity and is particularly a problem in OUD 
RCTs.  An intention-to-treat (ITT) analytic approach preserves the randomized sample size since 
all patients are analyzed, while a per-protocol (PP) approach excludes patients who did not have 
sufficient exposure to the assigned study treatment.  Regardless of an ITT or PP approach, 
patient failure to initiate treatment or non-adherence can compromise validity of results.  
Inverse probability weighting (IPW) is a method that can be used when non-adherence or 
missing data is prevalent in order to reduce bias in estimating the treatment effect.  In OUD 
RCTs, IPW is a novel method currently not widely used. This dissertation introduces the 
application of a new IPW approach, inverse probability of induction weighting (IPIW), to Cox 
regression.  Specifically, these methods will be applied to publicly available data from X:BOT, a
	 iv	
RCT that was conducted to compare buprenorphine-naloxone (BUP-NX) versus injectable 
extended-release naltrexone (XR-NTX) in 570 patients. 
In Chapter 2, both ITT and PP approaches will be used through time-dependent non-
proportional hazards models separately for outcomes of time to relapse, time to first positive 
opioid urine test, and time to overdose.  Chapter 3 will focus on IPW methods in modeling time 
to relapse.  IPIW will be introduced to account for differential induction status between treatment 
groups. Chapter 4 will outline a tutorial of how to compute IPIW that can be applied in many 
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CHAPTER 1: LITERATURE REVIEW 
 
 This chapter specifies the pertinent background necessary to understand the methodology 
provided in the following chapters.  Existing literature is reviewed to address induction failure, a 
type of noncompliance, in substance abuse randomized controlled trials (RCTs).  In RCTs, 
randomization is assumed to evenly distribute various factors among the treatment groups to 
ensure balance.  Specific biomedical research areas where balance between treatment groups is 
compromised for estimating treatment effect due to noncompliance are human 
immunodeficiency virus (HIV) and substance abuse RCTs.  Inverse probability weighting (IPW) 
methods include wide array of methods that have successfully been used in HIV research to 
address noncompliance and reduce bias in estimating the treatment effect.  This paper will adapt 
and apply IPW methods to the problems inherent in RCTs for substance abuse treatment.   IPW 
methods can be applied to any statistical model, but this dissertation will focus on the application 
of IPW methods to Cox models.  
 
1.1   Introduction 
1.1.1   Principles of analysis of randomized controlled trials  
Clinical trials are prospective designs used to evaluate exposures in patients due to some 
form of intervention.  The first clinical trial was performed accidentally by a surgeon treating
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wounded soldiers in 1537 (1).  Clinical trials have since evolved and the U.S. Food and Drug 
Administration (FDA) now has authority over the regulation and conduct of clinical trials for 
drugs and medical devices.  The FDA states that randomization and blinding are the “most 
important techniques for avoiding bias in clinical trials” (2).    
 
1.1.1.1   Advantages of randomized controlled trials 
In 1931 randomization was first introduced in a clinical trial involving patients and 
treatment of tuberculosis (3).  When Amberson et al. (3) conducted their study of tuberculosis 
treatment they considered randomization in the clinical trial in order to reduce any potential 
bias.  Bias refers to any deviation from the true value (4).   When clinical trials are well-
designed, randomization evenly distributes both observed and unobserved factors among the 
treatment groups, which reduces the potential for confounding (5).  If prognostic factors are 
balanced in the treatment groups and there is no treatment effect, then the proportion of patients 
experiencing the outcome will be similar between the groups (6).  Additionally, if prognostic 
factors are balanced in the treatment groups and there is a difference in the outcome between the 
groups, the differences can confidently be attributed to the treatment intervention (6). 
We can consider a simplistic linear regression statistical model that compares two 
treatment groups with a continuous outcome at a single follow-up evaluation: 
 
     𝑦 = 𝛽! + 𝛽!𝑥 + 𝜀       (1.1) 
 
such that 𝛽! and 𝛽! are constant regression coefficients, 𝜀 is the random error, and 𝑥 is the 
indicator variable where 𝑥 = 0 is for treatment 1 and 𝑥 = 1 is for treatment 2.  In any experiment 
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our purpose is to use statistical inference to estimate the parameters shown in Equation 1.1 where 
the estimates represent the true parameter values (7).  If we performed the same study multiple 
times, creating estimates for each study, then theoretically our estimates would center around our 
population parameters, leading to unbiased estimates (7).  For Equation 1.1, 𝛽! represents the 
true difference in efficacy between treatment 1 and treatment 2, and in a clinical trial we desire 
an unbiased estimate.   
 Patients selected to be in a clinical trial represent a sample of the patient population and 
should be carefully selected in order to reduce selection bias of the sample representing the 
targeted population (4).  In the traditional drug efficacy clinical trial, participants are recruited 
and enrolled according to several well-defined inclusion and exclusion criteria, which narrowly 
defines the target population, but limits the potential for confounding bias.  In practice, trial 
participants constitute “samples of convenience” – not randomly selected samples – yet are 
believed to be representative of a carefully defined external population.  Increasingly, pragmatic 
clinical trials seek to conduct inference in broadly defined populations in “real world” settings by 
applying fewer, if any, participant enrollment restrictions (8).  While these trials seek to increase 
generalizability of study results, such designs are more prone to violations of internal validity 
due to confounding bias that arises in studies of heterogeneous populations (9). 
Randomly allocating selected patients to the different treatment groups will help ensure 
our models produce valid, reduced biased statistical estimates.  Various implementations of 
randomization, including matching and stratification, may be employed to facilitate having a 
priori factors believed to be related to the study outcome variable balanced across treatment 
groups.  However, randomization may not completely eliminate all bias, particularly in smaller 
samples where random imbalance is more likely to occur.   
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1.1.1.2   Limitations of randomized controlled trials 
1.1.1.2.1   Challenges of open-label randomized controlled trials 
As discussed above, randomization is a technique used in clinical trials as an effort to 
reduce potential bias, but it does not completely eliminate all bias.  The FDA recommends that 
controlled trials be designed using randomization and blinding, if possible (2).  Blinding is an 
experimental condition that is used to eliminate bias from patients, staff, and statisticians 
assessing and interpreting results.  However, not all clinical trials can be masked.  An open-label, 
or unblinded, study is one in which all involved parties are aware of the treatment a patient is 
receiving.  Open-label studies are important to consider in order to protect patients’ medical 
safety.  However, due to the nature of open-label studies, unavoidable bias may be produced by 
knowledge of treatment arm (10). 
 
1.1.1.2.2   Generalizability 
            Although randomized controlled trials (RCTs) can produce results with strong internal 
validity, there are some limitations that arise from RCTs, such as lack of generalizability.  The 
FDA requires “substantial evidence of effectiveness” and safety of a drug to be addressed with at 
least two RCTs to ensure reproducibility and information regarding generalizability 
(4).  Reproducibility is defined as the ability to find similar results in a different study using the 
same methods and target population.  Generalizability is defined as a measure to determine how 
practical the results of a study are for a broader group of people.  In a sense, generalizability is 
the reproducibility of clinical results in a similar, but different, target population.  As expected, 
the response a patient has to a treatment varies between patients, and therefore the response is 
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expected to vary from the target population and a similar but different population (4).  Therefore, 
any estimated effects in a clinical trial can only be generalized back to the target population that 
the sample represents. 
 
1.1.2   Confirmatory trials 
Safety and efficacy are essential statistical principles demonstrated in RCTs to address 
reproducibility and generalizability (2).  A type of clinical trial that is used to evaluate safety and 
efficacy of treatments is a confirmatory trial.  A confirmatory trial is a type of clinical trial in 
which the hypotheses are stated a priori.  They are intended to provide evidence in support of 
claims being made while adhering to established protocols.  In confirmatory trials, athe estimated 
size of effects due to treatment should be calculated precisely and relate to the clinical 
significance of the drug (2).  Referring back to Equation 1.1, 𝛽! is the true difference in efficacy 
between treatments.  The goal of a clinical trial is to obtain unbiased estimates of this parameter 
(7).  Intention-to-treat (ITT) and per-protocol (PP) are two common approaches used in RCTs. 
  
1.1.2.1   Intention-to-treat 
In an ITT approach, all patients are analyzed in the group to which they were 
randomized.  ITT as defined by Fisher (1990), “Includes all randomized patients in the groups to 
which they were randomly assigned, regardless of their adherence with the entry criteria, 
regardless of the treatment they actually received, and regardless of subsequent withdrawal from 





1.1.2.1.1   Advantages and disadvantages of intention-to-treat in randomized controlled trials 
There are many benefits and limitations in using an ITT approach in a randomized 
controlled superiority trial.  ITT is an approach that ensures comparability between treatment 
groups due to randomization (11).  Since all randomized patients are used in an ITT approach, 
potential bias is reduced.  Another benefit in using an ITT approach is that the sample size is also 
maintained such that all patients will be analyzed regardless of premature withdrawal from the 
study.  Using an ITT approach will represent the effectiveness of a treatment rather than efficacy 
as the results obtained represent a clinical observation of real-life scenarios because people do 
not always adhere to treatment (11).  In clinical trials we want to avoid overestimating the effect 
of treatment such that the probability of a type 1 error is increased.  ITT is referred to as a 
conservative approach where the treatment effects are, if anything, under-estimated due to the 
fact that noncompliant patients are also included in the analyses and these patients presumably 
are associated with a negative outcome (12).  If noncompliance is assumed to occur equally in all 
treatment groups, any differences in treatment due to noncompliance are diminished to be closer 
to the null (12). 
However, if a treatment is effective but study attrition or non-adherence is high, an ITT 
approach can underestimate the magnitude of the treatment effect in patients who have adhered 
to the treatment (6).  Bias cannot be reduced in an ITT approach when it is caused by patients 
who are lost to follow-up or their outcome statuses are not known (6).  When a significant loss to 
follow-up occurs, an ITT approach provides little validity such that analyzing only patients 




1.1.2.2   Per-protocol    
Typically when patients have not adhered to the allocated treatment investigators will 
exclude these patients from the analyses, which is referred to as a PP approach and aims to 
address the true efficacy of a study.  A PP approach may also exclude patients who did not have 
a primary endpoint available or sufficient exposure to the study treatment (2).  This approach 
allows us to analyze the data to determine the treatment effect under an optimal scenario where 
patients are fully compliant (12).   If this approach is done alone, results could be biased to show 
an exaggerated treatment effect, as excluding all patients who did not adhere entirely to protocol 
does not represent a real life situation (11). 
  
1.1.2.2.1   Advantages and disadvantages of per-protocol in randomized controlled trials 
A PP approach can give biased estimations of treatment effect, which tend to 
overestimate the effect, but the effect can also be underestimated in some situations, and it is 
difficult to know the direction in which the bias will occur (2).  The effect is prone to bias 
especially if the reasons for excluding patients varies between the treatment groups (12).  Bias 
may be severe if adherence is related to the treatment and outcome (2).  If patients are 
experiencing adverse side effects related to treatment and are unable to complete the study, 
excluding these patients may make the treatment appear better than it actually is (11).  Previous 
studies have shown that patients who do adhere to treatment tend to do better than those who do 
not, even after adjusting for prognostic factors (13,14).  Randomization is then compromised if 
only adherent patients with better expected outcomes are analyzed as the groups are no longer 
considered balanced (11,15,16).  Excluding patients from the analyses may also reduce study 
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power due to the smaller sample size.  When the results of a PP and ITT approach differ 
considerably, further investigation is necessary. 
  
1.2   Implementation challenges for randomized controlled trials in specific biomedical 
        research areas 
 
Regardless of an ITT or PP approach, patient non-adherence can compromise validity of 
results and produce bias.  For medical treatment to be effective for a patient, a patient should 
adhere to treatment recommendations provided by their healthcare provider.  However, patient 
non-adherence to treatment is a common problem that affects all types of illnesses and includes 
failing to take given advice, taking the medication incorrectly, and forgetting or failing to take 
the medication (17).  Previous studies of various health conditions have reported that at least 
40% of patients fail to adhere to treatment recommendations (18–21) and when treatment is 
complex or requires lifestyle changes, non-adherence may be as high as 70% (22–24). 
In RCTs it is essential to maintain balanced treatment groups.  Patient retention in clinical 
trials is a critical aspect that ensures the groups stay balanced throughout the study.  However, 
clinical trials are voluntary and patients have the right to withdraw from the study at any time for 
any reason, such as adverse events, drug ineffectiveness, comorbidities, or death, which poses a 
threat to randomization.  HIV and substance abuse trials are biomedical research areas where 
balance between treatment groups is often compromised due to noncompliance.   
  
1.2.1   Human immunodeficiency virus research 
In HIV research there are many effective antiretroviral medications available for clinical 
use.  These medications can maximize efforts in suppressing HIV infection when properly used 
by patients (25).  However, if patients do not consume 95% of their medications, problems could 
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arise with viral resistance and therapeutic failure (25).  Poor adherence to medication and study 
protocol pose a great challenge for HIV clinical trials analyzing time to AIDS or 
death.  Statistical methods such as inverse probability of censoring weighting (IPCW) and 
restricted mean survival time are commonly used in HIV studies to address non-adherence in 
order to analyze the data properly.  
 
1.2.2   Substance abuse research 
Substance abuse clinical trials are also at a high risk of noncompliance due to the nature 
of the participants.  Patients are often unpredictable and have a diagnosis of substance 
dependence, therefore retention in opioid use disorder (OUD) studies is often low.  OUD studies 
often compare treatments to combat the disorder with common outcomes including relapse, 
retention in treatment, death, and overdose event.  Medication-assisted treatment (MAT) has 
been shown to be highly effective at treating OUD, but despite the effectiveness of MAT, the 
attrition rate is high.  One systematic review of 18 studies on MAT found that the average 
retention rate across all studies was about 50% (26).  Some studies report a retention rate as low 
as 10-20% (27–29).  Currently, there are no statistical methods commonly used to address non-
adherence and low retention in substance abuse clinical trials. 
  
1.3   Opioid use disorder  
OUD is a mental disorder defined by the Diagnostic and Statistical Manual of Mental 
Disorders (DSM-5) as a problematic pattern of opioid use leading to clinically significant 
impairment or distress.  Opioids come in the form of both illegal and legal pain relievers that can 
be natural or synthetic and are extremely addictive.  In the mid-to late 1990s there was a sharp 
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spike in the number of medical prescriptions written for opioids (30).  In 2016 there were more 
than 11.5 million Americans who reported opioid prescription misuse over the past year (31). 
Opioid-related deaths have also dramatically increased over recent years. Since 2000, 
there has been a 400% increase in the rate of overdose deaths involving opioids (opioid pain 
relievers and heroin) (32).  Between 2013 and 2014, the age-adjusted rate of death involving 
synthetic opioids other than methadone (e.g., fentanyl) increased 80% (32).  In 2016 opioids 
were involved in 42,249 (66.4%) drug overdose deaths, representing a 27.9% rate increase from 
2015 (32).  These increases primarily were driven by deaths involving synthetic opioids, for 
which the rate doubled from 2015 to 2016 (32). These findings indicate that the opioid overdose 
epidemic is worsening.  There is a need for continued action to prevent opioid abuse, 
dependence, and death, and improve treatment capacity for OUD (33,34). 
  
1.3.1   Therapies available for treatment 
The underlying cause of the overdose epidemic lies within patients suffering from 
substance-use disorder and the need for treatment (35).   MAT has been shown to be highly 
effective at treating OUD. There are currently three types of medications that have been 
approved for treating patients with OUD: methadone, buprenorphine, and naltrexone (35).  When 
used correctly, these medications have shown to be effective in patient recovery, as well as 
reduce the risk in overdose (35).  Although methadone has been shown to be highly effective for 
treating OUD, in the United States, methadone treatment is currently only available through 
MAT clinics (36).  Unlike methadone, buprenorphine and naltrexone are both available through 
primary care physician offices, as well as MAT clinics. 
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1.3.1.1   Naltrexone 
Naltrexone is a mu opioid receptor antagonist that blocks opioid effectiveness and does 
not result in any physical tolerance (37).  Extended release naltrexone (XR-NTX) is an injectable 
that was FDA approved in 2010 to prevent opioid dependence (37) and was originally used as 
treatment for alcohol dependence (38).  It reduces the tolerance of opioids and blocks the effects 
for approximately 28 days after it is administered (39).  XR-NTX requires that patients be 
completely detoxified from opioids before treatment.  In order for patients to avoid severe opioid 
withdrawal symptoms, it is recommended that they remain opioid-free for at least seven to ten 
days prior to initiation of XR-NTX (39).  XR-NTX must be administered by a trained healthcare 
provider (39). 
 
1.3.1.2   Buprenorphine 
Buprenorphine is a partial opioid agonist such that it binds to opioid receptors and 
produces opioid effects, but less severe than full agonists like heroin or methadone.  It’s 
properties offer patients less euphoria and physical dependence, a ceiling opioid effect, and 
relatively mild withdrawal symptoms (40).  Buprenorphine comes in a sublingual solution, 
sublingual tablet, combined buprenorphine-naloxone sublingual tablet or implant.  Naloxone is 
an opioid antagonist that blocks the effects of opioids.  Therefore, buprenorphine-naloxone 
(BUP-NX) is a partial agonist with antagonist properties and is effective in opioid use treatment 
in patients by reducing the risk of overdose (37).  SUBOXONE is a sublingual film combination 
of BUP-NX and is administered as a single daily dose (41).  When BUP-NX is initiated in 
patients with OUD, it should first be administered when moderate opioid withdrawal signs 
become apparent and no less than six hours after the patient’s last opioid use (41).  Treatment 
should first be monitored by a physician, but unsupervised administration is attainable given a 
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patient’s stability (41).  Several studies have shown effectiveness of regular buprenorphine 
treatment as compared to clonidine or tapering methods by showing strong evidence that patients 
on buprenorphine are more likely to complete detoxification and have negative illicit opioid drug 
tests (42,43). 
 
1.3.2   X:BOT Study 
1.3.2.1   Description of the study 
X:BOT is a comparative effectiveness study that was conducted from 2014 – 2016 to 
compare XR-NTX versus BUP-NX in patients for 24 weeks.  Eight study sites that had 
affiliations to the National Drug Abuse Treatment Clinical Trials Network were used to recruit 
570 patients who were 18 years or older, spoke English, had an opioid use disorder (as specified 
by the DSM-5), and had used any form of non-prescribed opioid in the last 30 days.  Patients 
were excluded from this study if they had any serious medical, psychiatric, or non-opioid 
substance use disorder.  Other exclusion criteria included transaminase concentrations greater 
than five times the upper limit of normal, suicidal or homicidal idealization, an allergy or 
sensitivity to XR-NTX or BUP-NX, had prior methadone maintenance treatment, had chronic 
pain requiring the use of opioids, legal obligations prior to the completion of the study, inability 
to safely receive intramuscular XR-NTX, and any women who were pregnant, breastfeeding, 
planning to conceive, or unwilling to use contraception. 
Patients were randomized in this open-label trial 1:1, stratified by treatment site and 
opioid use severity (high vs. low), such that high severity indicated greater than or equal to six 
bags or equivalent intravenous heroin use per day in the week prior to treatment 
admission.  Patients receiving XR-NTX required complete detoxification, negative opioid urine 
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test results, and a negative naloxone challenge, which included minimal opioid withdrawal 
symptoms following a dose of naloxone, a short-acting opioid antagonist (44).  XR-NTX 
injections (4 mL) were scheduled every 28 days starting no less than three days from the last 
dose of any opioid agonist (44).  BUP-NX was given as a sublingual film and treatment began 
once withdrawal symptoms appeared during detoxification.  Detoxification strategies varied by 
treatment site and some sites detoxed patients with a low maintenance dose of BUP-NX and 
others used methadone.  Individuals who detoxed with methadone were given BUP-NX no less 
than 24 hours after the last methadone dose (44).  BUP-NX (8-24 mg) was then dispensed at 
weeks 0,1, 2, 3, 4, 6, 8, 10, 12, 14, 16, and 20 for patients to self-administer daily.  Differential 
initiation of treatment was expected between treatment arms since XR-NTX required a complete 
detoxification but BUP-NX only required the onset of withdrawal symptoms (44). 
The primary goal of the X:BOT study was to determine whether there was a difference 
between XR-NTX and BUP-NX for the outcome of time to relapse (44).  Relapse was defined as 
either: “(a) four consecutive opioid use weeks, or (b) seven consecutive days of use by self-
report” (44). Secondary objectives included comparing clinical safety and efficacy outcomes for 
XR-NTX versus BUP-NX (44).  It was hypothesized that XR-NTX would produce greater opioid 
abstinence than BUP-NX (44), implying less risk of relapse for XR-NTX.  It was also 
hypothesized that both treatments would produce equivalent rates of serious adverse events, 
which included overdose events (44). 
 
1.3.2.2   X:BOT application of intention-to-treat and per-protocol 
The X:BOT dataset is publicly available through the National Institute on Drug Abuse 
Drug (NIDA) Share website (45) and is an example of substance abuse clinical trial data.  In this 
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study, induction status was defined as a binary variable indicating that if an individual had been 
dispensed BUP-NX or received XR-NTX injection then they were considered inducted into the 
study, otherwise individuals were considered to fail induction (46).  Lee et al. (2018) defined the 
ITT and PP approaches dependent on induction status such that every individual who was 
randomized to BUP-NX or XR-NTX was analyzed in the ITT approach.  The population used for 
the PP approach was determined by induction status such that all individuals who were inducted 
into the study were used.  Any individuals who had a failed induction status were excluded from 
the PP approach.   
The data were then analyzed using Cox models to measure the hazard ratio of the 
difference between treatment groups for time to first opioid relapse.  For ITT, Lee et al. (47) 
found a violation in proportional hazard of relapse, but no violation in the PP approach.  Though 
stating differences in results between ITT and PP was due to high proportion of relapse among 
XR-NTX induction failures, Lee et al. (47) did not apply any weighting techniques, despite 
hypothesizing that XR-NTX may have more dropouts after randomization and prior to induction 
compared to BUP-NX due to the differences in the induction process.  Therefore, time-
dependent and weighted Cox models will be considered in this dissertation to account for 
differential induction between treatment arms. 
 
1.4   Cox proportional hazards model 
The Cox proportional hazards model was created in 1972 for the purpose of analyzing 
censored failure times.  At that time, life tables were extensively used, but Cox proposed a more 
formal statistical theoretical approach that extended the work that Kaplan and Meier had done in 
regard to life tables.  In Cox’s method he proposed considering each individual in a study as 
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either time to “failure” or time to “loss” (censoring) such that the time to failure is greater than 
time to censoring (48).  Therefore for continuous failure time, T, the survival function and hazard 
failure rate are represented respectively as:  
 
     𝐹 𝑡 = 𝑃 𝑇 ≥ 𝑡       (1.2) 
  
    𝜆 𝑡 = lim∆!→!!
!(!!!!!!∆!|!!!)
∆!
    (1.3) 
 
Cox proportional hazards regression is a common statistical technique used in time-to-
event or survival analysis.  It has the ability to adjust for several risk factors or exposure with 
respect to survival time in order to measure the hazard rate, or instantaneous risk of failure, given 
that an individual has survived up to that time (49).  Therefore, to assess the relation between the 
distribution of failure time and covariates, z, the hazard can be modeled as: 
 
     𝜆 𝑡; 𝒛 = exp 𝒛𝜷 𝜆!(𝑡)     (1.4) 
 
where z is a 1×𝑝 vector of measurements, 𝜷 is a 𝑝×1 vector of unknown parameters and 𝜆!(𝑡) is 
an unknown function given the hazard function for the standard set of conditions z=0 such that 
the predictors have a proportional effect on the predicted hazard.  This model assumes nothing 
about the shape of the baseline hazard function, but does make assumptions on independence, 
proportionality of hazards over time, and a linear association between predictors and the natural 
logarithm of the relative hazard, and hence is considered a semi-parametric model.  The simplest 
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approach to the analysis of this family of regression models is to assume an underlying 
exponential distribution, therefore assuming 𝜆!(𝑡) as constant (48).   
 
1.4.1   Non-proportionality  
When the proportionality assumption is violated in a Cox proportional hazards model, 
further considerations should be implemented.  We can test the null hypothesis that the hazards 
are proportional throughout time, therefore indicating that the log hazard is constant.  Some of 
these tests include testing a linear time interaction, testing a logarithm of time interaction, or a 
Kolmogorov-type supremum test with simulated residual patterns.  However, just because we 
fail to reject the null hypothesis in these tests does not always imply that the proportionality 
assumption has been met.  This is due to the fact that specifying the alternative hypothesis is 
complicated such that there are many different ways that the hazards can depart from 
proportionality.  Hence, any statistical test that tests the null hypothesis of proportional hazards 
fails to account for all variations of a non-proportional hazard ratio.  Therefore a visual 
inspection of the hazard ratio or negative logarithm of the survival curve is important in 
assessing any departures over time because these departures can take many different forms.  One 
way to address a non-proportional hazards model is to allow for time-dependent covariates.  
 
1.5   Inverse probability weighting 
            Inverse probability weighting (IPW) is a class of methods that can be applied to any 
statistical model, but this paper focuses on application of IPW methods to Cox models.  IPW 
methods have successfully been used in HIV research for noncompliance, and in this paper we 
adapt and apply IPW methods to the problems inherent in RCTs for substance use 
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treatment.  IPW methods can be used when there is noncompliance in a study or when missing 
data are prevalent in order to reduce bias.  For example, missing data can cause bias if the 
individuals excluded in the analysis vary systematically from those included in the 
analysis.  IPW is used in survey data to correct unequal sampling fractions to ensure that an 
adequate number of individuals with the particular interest are chosen (50).  Weighting is also 
used to account for nonresponse to correct for bias in sample surveys (51).   In IPW, individuals 
with no missing data (complete cases) are weighted by the inverse of their probability of being a 
complete case.  IPW may be a preferred method when individuals have many covariates with 
missing values, such as in longitudinal studies where multiple variables are measured at each 
visit (50).  
In OUD clinical trials, IPW is a method currently not widely used, though there are 
benefits to initiating this approach with OUD data.  Currently IPW is commonly used for HIV 
data to account for high non-adherence.  Substance abuse data are similar to HIV data in the 
respect that non-adherence is typically high.  There are differences between HIV data and 
substance abuse data such that the reasons people do not adhere to the medication prescribed can 
be very different.  In HIV research, patients cannot always afford their medication or have a 
severe adverse reaction from the medication.  In OUD research, patients typically do not adhere 
to protocol as a direct impact of their disorder, leading to low retention in OUD clinical 
trials.  As previously discussed, low retention can compromise balance in a clinical trial, creating 
bias.  The use of IPW allows us to weight observations that will reduce bias due to non-
adherence in our models.  Three types of IPW will be discussed, which include inverse 
probability of treatment weighting, inverse probability of censoring weighting, and our newly 
proposed inverse probability of induction weighting. 
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1.5.1   Inverse probability of treatment weighting 
                  Inverse probability of treatment weighting (IPTW) is a method commonly seen in 
epidemiology research that allows us to account for bias from observed confounders.  It involves 
a propensity score, which is sometimes used as a covariate or stratification factor in regression 
models.  IPTW uses a propensity score to form a weight such that a pseudo-population is 
created.  Weighting is a method that is commonly used in survey sampling (52), but is applicable 
in any situation that nonrandomized treatment is being evaluated or whenever regression 
adjustment is necessary (53).  Using IPTW allows us to model the relationship between a 
covariate and treatment assignment.  
The propensity score for each individual is defined as 𝑝! = 𝑃(𝐴! = 1|𝑳𝒊 = 𝒍𝒊).  This 
gives us the probability that individual i received treatment A=1, conditional on covariates 
𝑳𝒊 = 𝒍𝒊 (54). The pseudo-population is created to represent a weighted group that is not identical 
to the population, but is a possibility that could have been sampled from a population that had no 
confounding (53).  Therefore the IPTW is defined as: 
 
    𝑇! = 𝐴! 𝑝! !! + 1− 𝐴! 1− 𝑝! !!    (1.5)   
 
The covariates and treatment group are independent of one another in the pseudo-
population (53).  Although IPTW is a useful statistical technique, it will not be illustrated in this 
paper since the methodological complexities of the Lee et al. (44) analysis do not show any 
major differences between treatment groups after individuals are inducted into the 
study.  However, there is a need to address the differential censoring and differential induction 
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between treatment groups.  Therefore, only inverse probability of censoring weighting and our 
novel approach of inverse probability of induction weighting will be explored in this dissertation. 
 
1.5.2   Inverse probability of censoring weighting 
Inverse probability of censoring weighting (IPCW) is a technique that is successfully 
used in longitudinal data analysis, and particularly HIV research to account for possible bias due 
to dropout or censoring from noncompliance (55).  Positive weights are created for the time prior 
to the date censored and weights of one are given to the time on or after censoring for each 
individual: 
 
    𝑊!" =
! !!"!! !! 
! !!"!! !!,!!"!!
!
!!!       (1.6) 
 
where Wij is the inverse probability of censoring weights for patient i on day j.  𝐶!" = 0 indicates 
that individual i remained uncensored before day j and 𝐶!" = 1 indicates otherwise.  𝑋! =
1 indicates individual i was randomized to treatment 1 and 𝑋! = 0 indicates individual i was 
randomized to treatment 2; and 𝑉!"!! is defined as a vector of time-fixed and time-varying 
covariates.  The weights 𝑊!" are inversely proportional to the conditional probability estimate of 
the remaining uncensored until day j (55). 
The numerator of the censoring weights indicates the conditional probability of 
remaining uncensored given randomization of treatment arm (55).  It allows us to stabilize the 
weights in the event that censoring differs greatly between the treatment groups (55).  The 
denominator of the censoring weights indicates the conditional probability of remaining 
uncensored given randomization of treatment arm, as well as time-fixed and time-varying 
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covariates (55).  We can apply these weights to a Cox model to obtain partial likelihood 
estimates of 𝛽 using IPCW, which will be further explained in Chapter 3.   
 
1.5.3   Inverse probability of induction weighting 
 Inverse probability of induction weighting (IPIW) is a novel application of IPW created 
specifically for substance abuse RCTs where treatment induction is high.  Induction is a term 
used in substance abuse studies to define the status that an individual has started taking a 
treatment after randomization.  The term does not indicate that an individual has successfully 
gone through treatment, only that they have been administered at least one dose of the assigned 
treatment.  IPIW is an approach that will help in the analysis of data where induction into one 
treatment group is more challenging than the other group.  It is different from IPTW in that the 
outcome of interest does not greatly differ between treatment groups itself, but simply that 
individuals are less likely to be inducted into one treatment group over the other for an array of 
various reasons, depending on the study at hand.  This method will create weights such that we 
will weight observations in order to find less biased estimates of the treatment effect and will be 
described and discussed in more detail in Chapters 3 and 4.   
 
1.6   Summary of research 
 This dissertation uses publicly available data from X:BOT to address challenges 
commonly found in substance abuse RCTs.  Chapter 2 focuses on efficacy and safety outcomes 
of time to first opioid relapse, time to first positive opioid urine test, and time to overdose.  Both 
ITT and PP approaches will be used to analyze the data, and statistical techniques will be applied 
in order to address a non-proportional hazard ratio over time.  Chapter 2 establishes the need for 
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additional statistical analyses that are necessary to correctly analyze this type of data with 
reduced bias in Chapters 3 and 4.  Chapters 3 and 4 focus on IPW methods regarding the efficacy 
outcome of time to relapse.   
Chapter 3 uses a Cox proportional hazards model with the outcome of time to first opioid 
relapse.  First, IPCW will be used to account for the differential censoring between treatment 
arms, though this does not fully remove bias from these estimates.  Therefore, the novel 
application of IPIW is developed.  Additionally, we propose combining IPCW and IPIW to 
account for both differential censoring and differential induction between treatment groups 
simultaneously.  This approach can conceptually provide a means for estimating the hypothetical 
scenario in which all patients remained in the study until the end of treatment and induction 
failure was identical in both arms, producing reduced biased estimates of treatment effect. 
Chapter 4 gives a detailed tutorial on how to create induction weights using SAS 9.4.  
The tutorial uses the X:BOT data to show detailed steps and explanations of IPIW using a Cox 
model with time to relapse outcome to account for differential induction.  OUD RCTs require 
analytical methods that can validly compare treatments while accounting for differences in 
induction proportions between arms.  The tutorial in Chapter 4 provides reference for RCTs in 
other research areas, in addition to substance abuse, such as viral infections and contraception 







CHAPTER 2: ANALYTICAL APPROACHES TO OPIOID USE DISORDER CLINICAL 
TRIAL DATA USING TIME-TO-EVENT MODELS 
 
 
2.1   Introduction 
Opioid use disorder (OUD) is a chronic condition that affects at least three million people 
in the United States and 16 million people worldwide (56). There are three medications that have 
been approved for abstinence-based OUD recovery (35):  buprenorphine-naloxone (BUP-NX), 
injectable extended-release naltrexone (XR-NTX), and methadone. Randomized open-label trials 
are the primary means of establishing safety and efficacy for OUD recovery.  However, there are 
numerous complexities in conducting trials.  These include loss to follow-up that may be 
differential between treatment, resulting in follow-up time that varies between subjects and is 
influenced by the outcome of randomization.  
This paper illustrates the use of two types of survival analysis models as a means of 
partially addressing these issues in the data analysis phase of a trial. We illustrate the use of two 
types of survival analysis regression models: standard Cox models that can be used to estimate 
the treatment effect on average across the entire follow-up period, and models with treatment-by-
time interactions, which can be used to estimate treatment effects that are specific to defined sub-
intervals of the overall follow-up period.    
 
2.1.1   Example randomized controlled trial: X:BOT trial 
X:BOT was a comparative effectiveness, randomized, multi-center, open-label, clinical 
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trial conducted from 2014 to 2016, comparing BUP-NX and XR-NTX over a 24 weeks follow-
up period. X:BOT (CTN-0051) was supported by the National Institute on Drug Abuse 
(NIDA).  The purpose of X:BOT was to determine the comparative effectiveness and safety of 
BUP-NX and XR-NTX. A total of 570 patients were 1:1 randomized (44).  The primary outcome 
of interest was time to relapse, where relapse was defined as the use of any non-prescribed 
opioids, starting 21 days after randomization.  Secondary outcomes of opioid use other than 
treatment medications, and adverse events, including overdose, were also analyzed (44). Non-
treatment opioid use during treatment was measured by a weekly patient report (57) and urine 
drug tests (46). Spontaneous adverse events were reported to study clinicians by study 
participants (37). 
Buprenorphine is a partial mu-opioid receptor agonist with antagonist properties. 
Naltrexone is a pure mu-opioid receptor antagonist. Therefore, both medications require patients 
to have metabolized and eliminated exogenous opioid agonists and to effectively be in early 
stages of withdrawal. In X:BOT, BUP-NX was provided as a daily, self-administered, sublingual 
film and was initiated once withdrawal symptoms appeared during detoxification. In contrast, 
patients receiving XR-NTX required complete detoxification, negative opioid urine test results, 
and a negative naloxone challenge test (44).  XR-NTX injections (4 mL) were scheduled every 
28 days.  
  Induction proportions differed between treatment groups. A total of 28% of patients in 
the XR-NTX arm, compared to 6% in the BUP-NX arm, were not able to be inducted into 
treatment (44).  The original analysis using an intention-to-treat (ITT) approach indicated that the 
risk of relapse was higher in the XR-NTX arm, compared BUP-NX arm (HR=1.36, 95% CI 
1.10–1.68) (44).  The original report of the study findings (hereafter referred as the original 
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report) noted that this was largely due to the early relapse among XR-NTX participants who did 
not complete induction (44).  Accordingly, the original report also presented a per-protocol (PP) 
type analysis, limited to participants who successfully inducted, concluding that the hazard of 
relapse was similar for XR-NTX and BUP-NX (HR 0.92, 95% CI 0.71–1.18) (44). 
An acknowledged limitation of this original report was that, in contrast to the primary 
outcomes, time-to-event (survival) models were not used for the urine and overdose outcomes. 
Thus, time-independent comparative effectiveness assessment for those two outcomes reported 
in the original paper (44) could potentially have been affected by the differences in induction and 
drop-out between the two arms (58).  Furthermore, the ITT and PP time-to-event analyses that 
were conducted assumed a constant treatment effect over time for the relapse endpoint. As noted 
in the original report, this was true for the PP models but not the ITT models (44). 
The primary purpose of this paper was to illustrate the usefulness of survival analysis and 
Cox models, particularly those involving treatment-by-time interactions, for the analysis of trials 
of treatments of opioid use disorder. To illustrate the use of these models, we analyzed the 
publicly available data from X:BOT (hosted on NIDA’s website) (45), to examine the efficacy 
(opioid relapse and positive opioid urine test) and safety (overdose events) outcomes using time-
independent and time-dependent survival models. Specifically, the models used in this paper 
illustrate simple (time-independent) Cox survival analysis models for time to relapse, time to 
overdose, and time to first non-negative opioid urine test. In addition, given the presence of time 
interactions in the ITT results presented in the original report (44), we also utilized Cox models 
with treatment-by-time interactions (time-dependent models) with the objective of identifying 
attempting to isolate effects during the treatment phase effects from the pre-treatment and post-
treatment phases.  
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2.2   Methods 
2.2.1   X:BOT trial design  
X:BOT was a randomized clinical trial that compared BUP-NX and XR-NTX over a 24 
weeks follow-up period on two efficacy outcomes (opioid relapse and positive opioid urine test) 
and one safety outcome (overdose).  Eight study sites were used to recruit patients who were 18 
years or older, spoke English, had an opioid use disorder (as specified by the Diagnostic and 
Statistical Manual of Mental Disorders-5), and had any form of non-prescribed opioid use in the 
last 30 days.  This open-label trial was conducted from 2014 to 2016.  
 
2.2.2   Patients 
Of the 570 patients in this study, the majority were white (78%), male (70%), and had an 
average age of 34 years. For the ITT approach, the public use data file contained 283 participants 
randomized to the XR-NTX group and 287 randomized to the BUP-NX group, identical to the 
treatment allocation numbers reported by Lee et al. (44).  Following the approach used to Lee et 
al. (44), for PP analyses we included only individuals who were inducted into the study. This 
yielded 204 individuals in the XR-NTX group and 270 individuals in the BUP-NX group, 
identical to the numbers reported by Lee et al. (44).   
  
2.2.3   Exclusion criteria 
Patients were excluded if they had any serious medical, psychiatric, or non-opioid 
substance use disorder. Other exclusion criteria included transaminase concentrations greater 
than five times the upper limit of normal, suicidal or homicidal idealization, an allergy or 
sensitivity to XR-NTX or BUP-NX, prior methadone maintenance treatment, chronic pain 
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requiring the use of opioids, legal obligations, inability to safely receive intramuscular injections, 
and any women who were pregnant, breastfeeding, planning to conceive, or unwilling to use 
conception.  
  
2.2.4   Survival analysis outcomes 
2.2.4.1   Time to relapse 
Opioid relapse was defined by Lee et al. (44) as “four consecutive weeks of any non-
study opioid use by urine toxicology or self-report, or seven consecutive days of self-reported 
use.”  The publicly available data files included a pre-constructed binary relapse outcome 
variable, which we used for our analysis. We analyzed time to relapse using Cox regression to 
compare treatment arms, where time to relapse was defined as non-study opioid use measured 
from the date of randomization (day 0). For the ITT analyses, individuals who were not 
successfully inducted were considered to have relapsed on the date of induction failure.   
  
2.2.4.2   Time to non-negative weekly urine test 
Lee et al. (44) analyzed weekly opioid-negative urine samples with a mixed-effect model 
where missing tests were considered positive.  A positive opioid urine test was defined as “non-
study opioids (buprenorphine, methadone, morphine [heroin, codeine, morphine], or 
oxycodone)” (44).  In this re-analysis, we created a new variable from the public-use urine 
toxicology data file (45) of opioid urine test results.  We defined a positive opioid urine test the 
same as Lee et al. (44) and analyzed the first positive opioid urine test for each individual, 
starting at randomization.  Individuals who had more than one positive test throughout the study 
were analyzed based on time of first positive urine test. In this re-analysis we considered missing 
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tests as positive, as Lee et al. (44), but also considered missing tests as missing to see to what 
extent the results were affected by the strong assumption that all missing tests would have been 
positive, had they been available.   
 
2.2.4.3   Time to overdose 
Overdose events were pre-coded on the publicly available data files as a binary variable 
for any overdose, using date of first overdose as reported spontaneously and supported by 
medical record review (37).  Only eight participants had an opioid specified as the substance 
involved overdose, but the adverse event reporting system used in X:BOT means substance 
could not guaranteed to have been systematically collected by the study procedures.  One 
participant had an unknown substance overdose and one participant had a “narcotic” 
overdose.  All other overdoses (n=17, 63%) in the dataset did not include a type of overdose.  
Thus, for our analysis, we included any overdose event, irrespective of the substance(s) involved. 
   
2.2.5   Data Analysis  
So as to be directly comparable to the original trial, unadjusted Cox regression was used 
to compare the two treatments using the hazard ratios for three outcomes: opioid relapse, positive 
opioid urine test, and overdose. For each outcome, patients who did not experience the outcome 
(opioid relapse, positive opioid urine test, or overdose event) were right censored on the 
participant’s last recorded date of observation.  We also conducted a Fisher’s Exact test with the 
publicly available data to directly analyze our overdose numbers using the methods documented 
in Lee et al. (44). 
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  In preparatory analyses, graphical inspection of the public use dataset demonstrated a 
strong violation (non-constant hazard ratio over time) in both the ITT and PP analyses for all 3 
outcomes: opioid relapse (Figure 2.1), positive opioid urine tests and overdose event outcomes. 
Thus, in time-dependent Cox models, time-by-treatment interactions were used to allow hazard 
ratios to be computed for three different periods of follow-up: pre-treatment, treatment, and post-
treatment. Following Lee et al. (44), the pre-treatment period started at day 0 until day 21, 
treatment was from day 22 until day 168 (24 weeks), and follow-up was defined as 169+ days. 
Use of time-by-treatment interactions allowed for safety and effectiveness outcomes during the 
treatment phase to be isolated from other time periods. The original trial report did not include 
any time-by-treatment interactions, but did describe non-constant hazard ratios over time in the 
ITT analyses and included a graphical presentation of non-constant hazard ratios. 
 
2.3   Results 
  Using the publicly available data from the X:BOT study (45), we were unable to fully 
replicate the results in the original report (44).  Specifically, there were small differences in 
counts of relapse, positive urine tests, and overdose events between the published results (44) 
and the counts that we computed from the publicly available data files (Table 1). The absolute 
differences were small, never larger than 5 for any outcome in any arm.  However, for the 
overdose outcome, the number of outcomes was low in this study of 570 participants. Therefore, 
the difference in overdoses was large as a proportion of the reported counts (i.e., about 30% 




2.3.1   Time to Relapse 
For the ITT analysis, the public data file contained 180 relapses in the XR-NTX arm 
(n=283) and 162 relapses in the BUP-NX arm (n=287), compared to 185 and 163 in Lee et al. 
(44) analysis, respectively.  For the PP analysis there were 101 relapses in the XR-NTX arm 
(n=204) and 145 relapses in the BUP-NX arm (n=270), compared to 106 and 150 in Lee et al. 
(44) analysis, respectively. Due to these slight differences between the Lee et al. (44) paper and 
the publicly available data, this re-analysis produced similar but slightly different hazard ratios 
(Table 2.1).   
The hazard of opioid relapse was 1.40 times as high (95%CI: 1.13, 1.73; p<0.01) in the 
XR-NTX arm than the BUP-NX arm on average during the course of the study using an ITT 
approach (Table 2.1).  Using models with treatment-by-time interaction, during treatment there 
was a 45% increase in the hazard of relapse for XR-NTX compared to BUP-NX (HR=1.45; 
95%CI: 1.17, 1.81; p<0.01) using an ITT approach (Table 2.2).   
Using the public data files we too found a higher percentage of opioid relapse for BUP-
NX (145/270) versus XR-NTX (101/204).  Although XR-NTX showed a slight protective factor 
for relapse prevention compared to BUP-NX with the PP approach (HR=0.89; 95%CI: 0.69, 
1.14), there was no statistically significant difference in opioid relapse over time between the two 
groups using this approach.  Lee et al. (44) stated that for the PP approach there was a higher 
percentage of opioid relapse events for the BUP-NX group (150/270) versus the XR-NTX group 





2.3.2   Time to non-negative urine test 
For the time to non-negative urine test analysis using an ITT approach, there was a 35% 
increase (HR=1.35; 95%CI: 0.98, 1.87; p=0.07) in the risk of a positive opioid urine test with 
XR-NTX compared to BUP-NX averaged over the entire observation period (Table 2.1).  
Treatment-by-time models indicated that this increase was concentrated in pre-treatment 
phase.  During pre-treatment the risk of a positive opioid urine test was 118% higher in XR-
NTX arm relative to the BUP-NX arm (HR=2.18; 95%CI: 1.33, 3.60; p<0.01).   
Using survival analysis, similar results were found when missing urine tests were 
considered missing and for the PP approach. This is in contrast to the analysis of the number of 
weekly opioid negative urine samples by Lee et al. (44). 
 
2.3.3   Time to overdose 
The public data file (45) contained 19 individuals in the XR-NTX arm (n=283) and eight 
individuals in BUP-NX (n=287) who had at least one overdose.  Lee et al. (44) reported fewer 
individuals (n=15) with overdoses in XR-NTX than the 19 found in the public data file. 
However, the total number of fatal overdose events in the public data file (45) was equivalent to 
the original report (44) (n=five events).  The original report (44) found no statistical difference in 
the proportion of overdoses between treatment arms using a Fisher’s Exact test.  Contrary to the 
conclusion of the original report (44) that “both treatments are equally safe once initiated,” we 
found a statistically significant difference between treatments when we performed a time-to-
event analysis.  Using a PP approach, we found there is a protective factor for overdose 
prevention with BUP-NX compared to XR-NTX (HR: 2.40; 95%CI: 0.95, 6.11). During 
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treatment the risk of overdose is 5.72 (1.21, 26.92) times as high in XR-NTX compared to BUP-
NX when using PP.  Similar results were found for an ITT approach.   
However, as noted above, the absolute number of outcomes was low in this study of 570 
participants. Although the number of discrepancies between our dataset and that for the original 
report are never more than 5 participants (Table 2.1), these are large as proportions of the 
reported counts (i.e., about 30% larger), and the discrepancies in overdoses fell entirely in the 
XR-NTX arm.  Therefore we conducted an additional analysis on our overdose counts, using 
methods similar to those used in the original report (44).  Specifically, we conducted a Fisher’s 
Exact test with the publicly available data, which showed statistically significant results for ITT 
(p=0.03) and marginally significant results for PP (p=0.10).  These suggest that the discrepancies 
between our results for overdose, and those of the original report (44), reflect not just the 
analysis methods, but also the differences in the underlying dataset utilized.  
 
2.4   Discussion 
  Our survival analyses concur with the conclusions of Lee et al. (2018) for the efficacy 
outcomes of relapse and positive urine test.  In contrast to the original report, our analysis 
indicated a greater risk of overdose for XR-NTX, predominantly during treatment. The 
differences in findings is due in part to relatively minor discrepancies in overdose counts (Table 
2.1) between the publicly available data and the original analysis performed by Lee et al. (44).  
Replication of analyses using publicly funded, publicly available clinical trial data are a critical 
tool for engendering confidence in major trials.  Using treatment-by-time interactions, we were 
able to isolate efficacy and safety effects during pre-treatment, treatment, and follow-up phases.   
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For the purpose of this analysis we have utilized both ITT and PP approaches, resulting in 
conflicting estimates for the time to relapse analyses.  Generally for efficacy outcomes it is more 
appropriate to use an ITT approach over a PP. In X:BOT, if we exclude patients due to non-
adherence (PP) then we can no longer consider the treatment groups balanced, and use of PP can 
result in selection bias and non-generalizability (11).  Lee et al. (44) correctly reports that since 
the results from the PP approach for opioid relapse were nonsignificant, there is no difference 
between the two groups once treatment is established, and fully acknowledge the differences in 
induction rates.  
Since patients who comply with treatment are generally considered to be different than 
those who do not adhere to treatment, results of a PP approach are often considered to have 
limited practical clinical validity unless drop out is assumed to occur completely at random 
(59).  However, in this study it is clear that drop out is not at random, as the initiation of XR-
NTX is more difficult than BUP-NX with a large percentage (28%) of individuals who were not 
inducted into the XR-NTX arm.  In our analyses using the public data files, and in the original 
report, the hazard ratios for opioid relapse differ considerably for the ITT and PP approaches.   
Our time-dependent analyses using an ITT approach showed that during pre-treatment 
and treatment there is an increased risk of opioid relapse for XR-NTX compared to BUP-NX, 
but during post-treatment, there is a decreased risk of opioid relapse for XR-NTX compared to 
BUP-NX.  This could indicate that although individuals have a more difficult time initiating XR-
NTX treatment, long-term results could be promising. Therefore, it would be reasonable to make 
both treatment modalities available to patients, and have a clinical plan to switch to agonist 
therapy for those who discontinue XR-NTX early. In routine medical care, XR-NTX 
discontinuation after 30 days was reported in more than half of patients (60).  
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The X:BOT study demonstrated that the drop out rate for XR-NTX is high during the 
first three weeks, and ultimately this complicates the conclusions from this trial regarding 
treatment effectiveness clinically when deciding between these two drugs.  Knowing that it is 
more challenging to initiate XR-NTX than BUP-NX should encourage clinicians to monitor 
patients on this medication more closely during the initial three weeks, provide harm reduction 
support, and make both agonist therapy available for those who discontinue.   
In contrast to opioid relapse, our results for positive opioid urine test and overdose events 
did not differ between ITT and PP approaches.  However, results for the time-dependent positive 
urine test analysis differed between time periods.  During pre-treatment and follow-up, there is 
an increased risk of positive opioid urine tests for XR-NTX compared to BUP-NX, but during 
treatment, there is a decreased risk.  We found conflicting results for our time to overdose 
analysis compared to the Fisher’s Exact test performed by Lee et al. (44).  We found statistically 
significant results for the risk of overdose for XR-NTX compared to BUP-NX during treatment 
and marginally statistically significant results across all time periods, however, this analysis 
reflects small numbers of overdoses.  In contrast, Lee et al. (44) did not find any difference in the 
proportion of overdoses between treatment arms. This discrepancy between our results and those 
of the original report are largely related to our inability to exactly reproduce their case counts for 
overdose (Table 2.1).  
  Finally, we observed a difference in the magnitude of the HRs between the opioid relapse 
and opioid urine models. It might be natural for a participant to experiment with opioid use and 
experience the negative reinforcement of attenuated psychotropic effects of opioids while under 
naltrexone mu-opioid receptor blockade. XR-NTX pharmacokinetics may also be at play. XR-
NTX has an initial plasma concentration peak at 2 hours post administration, and a second peak 
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2-3 days later, with declining levels after 14 days (39). There may be differences in the 
completeness of blockade between XR-NTX and BUP-NX, whereby mild intoxicating effects of 
opioids may be discernible with the latter.  During the pre-treatment period there were 75% of 
the XR-NTX group and only 48% of the BUP-NX group to test positive for opioids.  If 
experimentation during the early stages of treatment is a natural course of treatment, the 
pharmacological properties of treatment choice may directly influence induction proportions. 
This has impact on clinical treatment delivery. A harm reduction approach during induction with 
XR-NTX would be ethically responsible knowing that continued use is highly prevalent and that 
other treatments afford greater protection from use during this period. 
   Our approach has several limitations, mainly that we were unable to completely replicate 
the results from Lee et al. (44).  While we found had very similar counts for opioid relapse and 
overdose events compared to Lee et al. (44), the final outcome variable and programming code 
used in the original report were not available to us.  As Lee et al. (44) has indicated, the X:BOT 
study was not powered to find differences between the two groups for overdose events, leading 
to small numbers in our overdose re-analysis.  
 
2.5   Conclusions 
These time-dependent analyses illustrate the expanded use of survival models, 
particularly models with treatment-by-time interactions, in trials of substance misuse treatment 
programs.  Results from these models largely concur with the conclusions of Lee et al. (44), 
particularly for the efficacy outcomes of relapse and positive urine test.  However, for the safety 
outcome (overdose), these models indicate there is a greater risk of overdose for XR-NTX 
compared to BUP-NX during treatment.   
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 Time Since Randomization Time Since Randomization 
Figure 2.1 Negative log survival curve for time to first opioid relapse event, first  
























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































CHAPTER 3: INVERSE PROBABILITY OF CENSORING WEIGHTING AND 
SUBSTANCE ABUSE CLINICAL TRIALS AND THE INTRODUCTION OF INVERSE 




Randomization is a key component of a randomized controlled trial (RCT) but high rates 
of attrition and/or high induction failure poses a threat to the validity of a clinical trial and are 
particularly problematic in opioid use disorder (OUD) clinical trials.  Induction failure refers to 
when a trial participant has been randomized, but never receives a dose of treatment.   One 
approach to reduce bias by ensuring exchangeability between treatment groups is to use an 
intention-to-treat (ITT) approach.  ITT preserves the randomized sample size at optimal levels, 
since all patients who have been randomized are used in the analysis.  An alternative approach 
would be to use a per-protocol (PP) approach where patients who did not have sufficient 
exposure to the study treatment are excluded.  Regardless of an ITT or PP approach, patient non-
adherence can compromise validity of results and produce bias.  Patient non-adherence is a 
problem found in all RCTs and compromises the balance between groups.  Human 
immunodeficiency virus (HIV) and substance abuse clinical trials are two biomedical research 
areas where noncompliance is high. 
In HIV research there have been advances to accommodate statistical models that address 
noncompliance.  Many HIV clinical trials focus on time to acquired immunodeficiency 
syndrome (AIDS) or time to death, and inverse probability of censoring weighting (IPCW) is one 
commonly used method that addresses non-adherence in these studies.  IPCW corrects for
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noncompliance by weighting the days prior to censoring such that the effect of treatment will not 
be underestimated due to this issue. 
Noncompliance is also high in substance abuse clinical trials due to the nature of the 
participants.  Most substance abuse patients suffer from comorbid mental disorders (61) and the 
National Bureau of Economic Research (2002) states, “There is a definite connection between 
mental illness and the use of addictive substances.”  Patients often have a diagnosis of substance 
dependence, therefore retention in opioid use disorder (OUD) studies is often low.  Additionally, 
although there are similarities in HIV and substance abuse data, there are currently no known 
statistical methods commonly used to address a particular type of non-adherence in substance 
abuse clinical trials related to timing of treatment initiation, referred to as induction.  This paper 
introduces inverse probability of induction weighting (IPIW) such that these weights are used to 
generate a pseudo-population where induction and treatment are independent of one another 
(53).  The idea behind the pseudo-population is to create a weighted group such that it could 
have been from a population that had no confounding (53).  For instance, if an individual is 
inducted in a treatment group that has a low proportion of inducted individuals, we would want 
to weight their outcome with a large weight.  This paper introduces various inverse probability 
weighting (IPW) methods that can be applied to statistical models involving substance abuse 
data. 
 
3.2 X:BOT data 
  The X:BOT dataset is publicly available (45) and is representative of studies with 
problems commonly found in substance abuse clinical trials, specifically the issue of non-
adherence.  The X:BOT study is a multi-center, open-label, randomized controlled trial that 
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compared the effectiveness of extended-release naltrexone (XR-NTX) versus sublingual film 
buprenorphine-naloxone (BUP-NX) for opioid relapse prevention.  There were 570 patients who 
were randomized 1:1 to receive either XR-NTX or BUP-NX.   
 Lee et al. (45) stated in their results of this trial that induction into the XR-NTX group 
was more difficult than induction into the BUP-NX group as evidenced by lower success rates, 
but nonetheless they did not account for the differences of induction in their analysis.  Lee et al. 
(45) found that 94% of individuals in the BUP-NX group were inducted into the study, but only 
72% of individuals were successfully inducted into the XR-NTX group.  Using the publicly 
available X:BOT data (45), we confirmed the results of Lee et al. (45) and found that 270 out of 
287 (94%) individuals and 204 out of 283 (72%) individuals were inducted into the BUP-NX 
and XR-NTX groups, respectively.   
Though Lee et al. (45) found that both medications were equally safe and effective, their 
analysis did not account for the relatively large percentage of individuals who were not inducted 
into the XR-NTX group.  We will account for differential treatment induction using an intention-
to-treat (ITT) approach coupled with novel inverse probability of induction weights, which will 
be explained in further detail in upcoming sections.  Additionally, we will account for 
differential loss to follow-up in the X:BOT trial within the ITT framework using inverse 
probability of censoring weighting (IPCW).  Failure to correct for this differential loss to follow-






3.3 Methods  
3.3.1 Inverse probability of censoring weighting (IPCW) 
IPCW is a technique that has previously been used for HIV research to correct for 
noncompliance (55,63), but, to our knowledge, has never been used for opioid relapse outcomes 
to account for differential censoring rates between treatments.  It is an important statistical 
method that we are recommending for the substance abuse field due to the inconsistent and 
unpredictable nature of substance abuse patients that lead to high rates of loss to follow-up. 
IPCW is a method that can be used to correct discrepancies between compliant and 
noncompliant randomized evidence (55).  The weights created can be applied to any statistical 
model, but we will focus on a time-to-event model.  The censoring weights as defined by Cain 
and Cole are calculated as follows (55): 
 
    𝑊!" =
! !!"!! !! 
! !!"!! !!,!!"!!
!
!!!         (3.1) 
 
such that Wij is the inverse probability of censoring weights for patient i on day j;  𝐶!" = 0 
indicates that individual i remained uncensored before day j and 𝐶!" = 1 indicates otherwise;  
𝑋! = 1 indicates individual i was randomized to XR-NTX treatment and 𝑋! = 0 indicates 
individual i was randomized to BUP-NX treatment; and 𝑉!" is defined as a vector of time-fixed 
(at baseline) and time-varying covariates.  The weights Wij are inversely proportional to the 
conditional probability estimate of the remaining uncensored individuals until day j (55).  
The numerator of the censoring weights indicates the probability of remaining 




 𝑃 𝐶!" = 𝑐 𝑋!        (3.2) 
The denominator of the censoring weights indicates the probability of remaining uncensored 
until day j assuming no informative censoring given randomization of treatment arm as well as 
time-fixed and time-varying covariates (55): 
 
 𝑃 𝐶!" = 𝑐 𝑋! ,𝑉!"!!       (3.3) 
 
3.3.1.1 Partial likelihood estimates and IPCW 
We can apply the censoring weights to a Cox proportional hazards model to obtain partial 
likelihood estimates of 𝛽 using IPCW.  The use of partial likelihood allows a likelihood 
estimation that can be calculated without knowledge of 𝜆!(𝑡), where 𝜆!(𝑡) is an unknown 
baseline hazard function. Therefore the application of IPCW to a Cox model implies that the 
partial likelihood is:  
 




!!!       (3.4) 
 
where      𝑅 𝑡 = {𝑖 ∶ 𝑌! > 𝑡}      (3.5) 
 
is the risk set that represents the group of individuals who are at risk for failure time t and 𝑌! is 




3.3.2 Inverse probability of induction weighting (IPIW) 
Induction is a term commonly used in substance abuse clinical trials to indicate a 
participant has been assigned a treatment and has received at least one dose.  Sometimes there is 
a large variation of induction between the treatment groups for various reasons.  For example, in 
the X:BOT study the day of induction is the number of days since the randomization date (i.e., 
day 0) when an individual is inducted or fails induction, and notably the detoxification process 
differed substantially between the two treatment groups XR-NTX and BUP-NX: XR-NTX 
induction required a complete detoxification but BUP-NX induction only required the onset of 
withdrawal symptoms (44).  This difference resulted in differential induction in the X:BOT 
study.  It is important to account for these differences in the analysis, otherwise the results may 
be invalid due to overestimating or underestimating the effect of treatment. Therefore, we have 
created an application of a novel IPW method, called inverse probability of induction weighting 
(IPIW), to address differential induction proportions.  The weights will account for bias due to 
the higher induction failure and longer time to induction in the XR-NTX group.  
IPIW has been created specifically for substance abuse clinical trials where induction 
failure is high or induction timing varies greatly between arms.  IPIW is an approach that will 
help analyze data where induction into one treatment group is more challenging than for the 
other group.  In the X:BOT study there were 79 (27.9%) participants in the XR-NXT group who 
were not inducted but only 17 (5.9%) participants in the BUP-NX group who were not inducted.  
All failed inductees relapsed during the study.  Fisher’s exact test shows statistically significant 
results (p<0.01) such that the proportion of people inducted is statistically different between 
treatment groups.  This should be accounted for in any analysis performed in order to correctly 
adjust for differential induction status.  Once people were inducted into the treatment group, the 
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proportion of relapses were similar for XR-NTX and BUP-NX at 50% and 54%, respectively.  
Additionally, since the differences are not specifically accounted for by treatment, but induction 
into treatment, methods such as inverse probability of treatment weighting would not adequately 
adjust these models.  
Therefore, IPIW offers a noteworthy solution to account for differential induction 
between treatment groups.  This method will create weights according to induction status to find 
reduced biased estimates of treatment effect.  The weights will penalize the group with the higher 
induction failure, therefore creating a means for estimating the hypothetical scenario in which 
induction failure was identical in both arms.  Induction weights will be defined as: 
 
    𝜔!" =
! !!"!! !! 
! !!"!! !!,!!"!!
!
!!!       (3.6) 
 
such that 𝜔!"  is the inverse probability of induction weights for patient i on day j where day 0 is 
the date of randomization when detoxification begins;  𝜃 is an indicator variable such that 
𝐼!" = 0 indicates that individual i has yet to be inducted into the study before day j and 𝐼!" =
1 indicates otherwise;  𝑋! = 1 indicates individual i was randomized to XR-NTX and 𝑋! = 0 
indicates individual i was randomized to BUP-NX; and 𝑉!"!! is defined as a vector of time-fixed 
and time-varying covariates.  The weights 𝜔!" are inversely proportional to the estimated 
conditional probability of induction among the remaining individuals who have yet been 
inducted into the study on day j.  Once individuals have been inducted into the study, they are 
assigned a weight of 1.  The use of these weights in the partial likelihood for Cox models 
analogous to Equation 3.4 will allow us to model the counterfactual in which there is a common 
distribution of time to induction across treatments arms.   
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3.3.3 Variable selection 
3.3.3.1 IPCW 
The censoring weights were created by considering predictors of relapse and censoring 
using both a Cox model for the hazard of relapse along with a logistic regression model for the 
odds of censoring (versus not), shown in Table 3.1. The variables that met our pre-specified 
criteria of a p-value 0.20 or lower or a hazard ratio or odds ratio less than 0.75 or greater than 
1.33 for both hazard ratio of relapse and odds ratio of censoring included age, race/ethnicity, 
primary opioid used in the seven days before detoxification admission, Hamilton Rating Score, 
psychotic episode history, and Opiate Withdrawal Scale.   
    
3.3.3.2 IPIW 
In order to find the impact of induction failure, a similar process of finding predictors can 
be performed for induction status.  In addition to modeling the hazard of relapse, we also 
modeled the logit of not being inducted (versus inducted) using the characteristics listed in Table 
3.1.  We found race, primary opioid used in the seven days before detoxification admission, and 
Opiate Withdrawal Scale (categorical) fit our pre-specified criteria of a p-value 0.20 or lower or 
a hazard ratio or odds ratio less than 0.75 or greater than 1.33 for both hazard ratio of relapse and 
odds ratio of not inducted and therefore only those three variables were included in the induction 
weights.  This criterion indicates predictors with meaningful associations to relapse and/or 




Table 3.1. Hazard ratios of relapse, odds ratios of censoring relapse, and odds ratio of induction 
adjusted by treatment (n=570) 






















283 287 1.40 (1.31, 
1.73) 
<0.01 0.75 (0.53, 
1.05) 
0.09 0.16 (0.09, 
0.28) 
<0.01 
Male vs. female            
     Male 195 (69%) 206 (72%) 1.10 (0.87, 
1.39) 
0.43 0.93 (0.64, 
1.34) 
0.68 0.80 (0.48, 
1.36) 
0.39 
     Female 88 (31%) 81 (28%)          






         
    IQR 15 0.87 (0.73, 
1.03) 
0.10 1.29 (0.99, 
1.67) 
0.06 0.84 (0.59, 
1.19) 
0.32  
    25th 
Percentile 
27 26          
    75th 
Percentile 
39 39          
Age (years) – 
categorical  
           
     ≤26 68 (24%) 79 (28%)          
     27 – 31  69 (24%) 71 (25%) 0.85 (0.63, 
1.14) 
0.27 1.25 (0.77, 
2.02) 
0.37 1.05 (0.54, 
2.04) 
0.70 
     32 – 39  80 (28%) 66 (23%) 0.88 (0.66, 
1.18) 
0.38 1.20 (0.75, 
1.93) 
0.45 0.88 (0.47, 
1.67) 
0.64 
     ≥40 66 (23%) 71 (25%) 0.78 (0.58, 
1.06) 
0.12 1.47 (0.91, 
2.38) 
0.11 0.94 (0.49, 
1.83) 
0.91 
Race/Ethnicity            
    Black vs. 
White/other 
37 (13%) 36 (13%) 1.55 (1.14, 
2.11) 
0.01 0.60 (0.35, 
1.03) 
0.07 0.78 (0.42, 
1.48) 
0.80 
    Hispanic vs. 
White/other 
42 (15%) 51 (18%) 1.40 (1.05, 
1.85) 
0.02 0.66 (0.41, 
1.06) 
0.09 0.52 (0.28, 
0.98) 
0.11 
    White/other 204 (72%) 200 (70%)          
Intravenous 
drug use vs. 
other drug 
route 
177 (63%) 183 (64%) 1.08 (0.86, 
1.35) 
0.50 0.86 (0.60, 
1.22) 








           
    
Buprenorphine 
vs. heroin 
6 (2%) 2 (1%) 0.97 (0.40, 
2.36) 
0.95 1.09 (0.26, 
4.63) 
0.91 0.96 (0.18, 
5.12) 
0.04 
    Opioid 
analgesics vs. 
heroin 
43 (15%) 47 (16%) 0.65 (0.48, 
0.90) 
0.01 1.64 (1.04, 
2.59) 
0.03 2.07 (0.98, 
4.39) 
0.08 
    Methadone 
vs. heroin 
3 (1%) 4 (1%) 0.50 (0.16, 
1.57) 
0.24 2.21 (0.49, 
10.01) 
0.31 - - - 
    Heroin 230 (81%) 233 (81%)          
Primary opioid 




           





52 (18%) 53 (18%) 0.66 (0.49, 
0.89) 
0.01 1.62 (1.06, 
2.49) 
0.03 2.02 (1.01, 
4.02) 
0.05 
     Heroin 230 (81%) 233 (81%)          
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opiates) 
    IQR 8 0.95 (0.84, 
1.07) 
0.41 1.08 (0.89, 
1.31) 
0.43 0.79 (0.61, 
1.03) 
0.08  
    25th 
Percentile 
16 17          
    75th 
Percentile 
25 24          
Duration of 
opioid use 








         
    IQR 10 0.97 (0.88, 
1.07) 
0.58 1.03 (0.88, 
1.21) 
0.68 1.04 (0.83, 
1.30) 
0.73  
    25th 
Percentile 
5 5          
    75th 
Percentile 
15 15          
Substance use 
over past 30 
days from 
baseline 
           
    Alcohol 
Intoxication 
84 (30%) 85 (30%) 0.90 (0.71, 
1.13) 
0.36 1.11 (0.77, 
1.60) 
0.58 1.46 (0.86, 
2.48) 
0.16 
    Cannabis 140 (49%) 143 (50%) 1.00 (0.81, 
1.24) 
0.99 1.11 (0.79, 
1.56) 
0.55 1.44 (0.90, 
2.28) 
0.13 





133 (47%) 166 (58%) 0.99 (0.80, 
1.22) 
0.91 0.93 (0.66, 
1.31) 
0.69 1.00 (0.63, 
1.58) 
0.99 





87 (31%) 99 (34%) 1.13 (0.90, 
1.41) 
0.28 0.78 (0.54, 
1.13) 








9.30 (6.63)          
    IQR 10 1.13 (0.96, 
1.34) 
0.13 0.90 (0.70, 
1.17) 
0.44 1.06 (0.74, 
1.51) 
0.76  
    25th 
Percentile 
4 4          
    75th 
Percentile 
13 14          
Psychotic 
episode history 
vs. no history 
           
    Psychotic 
episode history  
7 (2%) 8 (3%) 1.80 (1.01, 
3.21) 
0.05 0.37 (0.10, 
1.32) 
0.12 1.29 (0.27, 
6.16) 
0.75 
    No psychotic 
episode history 
276 (98%) 279 (97%)          
Psychiatric 
disorder 
history vs. no 
history 
           












190 (67%) 191 (67%) 1.01 (0.80, 
1.27) 
0.93 0.91 (0.64, 
1.30) 






    No 
psychiatric 
disorder history 








6.49 (3.18)          
    IQR 4 1.19 (1.04, 
1.36) 
0.01 0.81 (0.65, 
0.99) 
0.04 0.74 (0.55, 
1.00) 
0.05  
    25th 
Percentile 
5 5          
    75th 
Percentile 






           
     ≤5 101 (36%) 98 (34%)          
     6 – 7  52 (18%) 51 (18%) 1.11 (0.81, 
1.52) 
0.51 0.85 (0.52, 
1.38) 
0.51 0.88 (0.44, 
1.76) 
0.71 
     8 – 9  53 (19%) 74 (26%) 1.17 (0.88, 
1.57) 
0.28 0.71 (0.45, 
1.13) 
0.15 0.74 (0.38, 
1.42) 
0.36 
     10 77 (27%) 64 (22%) 1.42 (1.08, 
1.87) 
0.01 0.64 (0.41, 
1.01) 


















3.3.4 Statistical analysis 
3.3.4.1 IPCW 
The denominator of the censoring weights was created using logistic regression to model 
the logit of an individual remaining uncensored until day j with the predictors of time, age, 
race/ethnicity, primary opioid used in the seven days before detoxification admission, psychotic 
episode history, Opiate Withdrawal Scale, treatment, and the interaction of time and 
race/ethnicity, primary opioid used in the seven days before detoxification admission, Opiate 
Withdrawal Scale, and treatment.  This analysis produced estimates of the denominator of the 
censoring weights for each individual on each day of the study until they either relapsed or were 
censored.  The numerator of the censoring weights was created using logistic regression to model 
the logit of remaining uncensored until day j and included only treatment, time, and the 
interaction of treatment and time in order to stabilize the weights and improve efficiency of the 
treatment estimate over time (64).  This analysis produced estimates of the numerator of the 
censoring weights for each individual on each day of the study.  The censoring weights were 
then created by taking the ratio of the numerator and denominator estimates for each individual 
on each day such that each individual had a different censoring weight for each day of the study.  
An unadjusted Cox model that includes the censoring weights to account for the differential 
censoring between treatment groups was used to model the hazard of relapse to compare the 
treatment arms.  
 
3.3.4.1.1 Censoring techniques 
 Using IPCW we are able to account for differential censoring between treatment groups 
in order to find adjusted hazard ratios of relapse, reducing bias caused by the censoring 
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differences. If the censoring between treatment groups does not differ then IPCW will not have 
an impact on the hazard ratios.  An important issue to consider in an analysis involving substance 
abuse data such as this is how to manage censoring.  When we use the IPW methods we use the 
ITT approach such that all individuals who were randomized are included in the analysis.  
However, we have to consider how to address individuals who were not inducted and therefore 
did not actually receive the medication.  Instead of removing these individuals completely, as in 
the PP approach implemented by Lee et al. (44), we can use different weighting techniques to 
investigate the effect of treatment. 
 In the X:BOT data, the majority of the participants (76%) who failed induction in the 
XR-NTX group failed induction due to meeting criteria for relapse (Table 3.2).  In the BUP-NX 
group, the majority of the failed inductees (59%) did so due to rejecting treatment.  Therefore, 
consideration was given as to how failed inductees should be managed in regard to the outcome 
since all of the individuals who were not inducted had a relapse event at some point during the 
study.  Three IPCW models were considered and created, each managing censoring of the failed 
inductees differently.  Model 1 considered all failed inductees to have relapse events, and anyone 
who was inducted into the study was either censored or relapsed.  Model 2 considered failed 
inductees who did so due to relapse to have relapse events on their failed induction date.  Failed  
 





Failed naloxone challenge 1 (1%) 0 (0%) 
Left prior to induction 4 (5%) 2 (12%) 
Rejected treatment 13 (16%) 10 (59%) 
Met criteria for relapse 60 (76%) 5 (29%) 
Reached end of induction window 1 (1%) 0 (0%) 
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inductees who failed due to reasons other than relapse were censored on their failed induction 
date.  Anyone who was inducted into the study was either censored or relapsed.  Lastly, Model 3 
censored all failed inductees on the failed induction date; all inducted individuals were either 
censored or relapsed. 
 
3.3.4.2 IPIW 
 The application of induction weights is similar to the process of applying censoring 
weights, such that we use logistic regression models to calculate the induction weights.  The 
denominator of the induction weights was created using logistic regression to model the 
conditional probability of remaining not inducted as a function of 𝑉!"!!, which included 
continuous time in days, race, primary opioid used in the seven days before detoxification 
admission, Opiate Withdrawal Scale, treatment, and the pairwise interaction of time with each of 
those covariates: 
 
   logit 𝑃 𝐼!" = 𝜃 𝑋! ,𝑉!"!! =  𝛾! + 𝛾!𝑋! + 𝛾!!𝑉!"!!    (3.7) 
 
 
This analysis produced estimates of the denominator of the induction weights for each individual 
on each day of the study until they either were inducted or failed induction. 
The numerator of the induction weights was created using logistic regression to model 
the the conditional probability of remaining not inducted as a function treatment and time: 
  
   logit 𝑃 𝐼!" = 𝜃 𝑋!  = 𝛿! + 𝛿!𝑋! + 𝛿! 𝑡𝑖𝑚𝑒! + 𝛿! 𝑡𝑖𝑚𝑒! 𝑋!   (3.8) 
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This analysis produced estimates of the numerator of the induction weights for each 
individual on each day of the study until they either were inducted or failed induction.  This 
technique of modeling both a numerator and a denominator has the effect of stabilizing the 
weights, i.e., limiting extreme estimating values for the weights.  The induction weights were 
then created by taking the ratio of the numerator and denominator estimates for each individual 
on each day such that each individual had a different induction weight for each day of the study.  
The induction weights will allow us to give a relatively larger weight to individuals with a low 
probability to be in the study on day k but still yet to be inducted compared to individuals with a 
higher probability of being in the study on day k but yet to be inducted.  Once an individual was 
inducted to the study, the induction weight was set to 1 for the remaining days until they either 
relapsed or were censored. To address the problem of differential induction, all failed inductees 
were censored on their date of failed induction.  This differs from how failed inductees were 
handled with IPCW because these individuals would not otherwise be considered censored 
observations in a standard ITT analysis.   
An unadjusted Cox model that includes the induction weights to account for the 
differential induction between treatment groups was used to model the hazard of relapse to 
compare treatment arms.  
 
3.3.4.3 Accounting for differential censoring and differential induction simultaneously 
To create estimates with controlled bias from confounders when differential censoring 
and differential induction are both present, we propose combining IPCW and IPIW methods 
together to create new weights: 
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 𝜛!" = (𝑊!")(𝜔𝑖𝑗)     (3.9) 
 
  The weights created from the IPCW Model 1 are multiplied by the induction weights.  
Therefore all individuals who were not inducted will be censored on their failed induction date 
and individuals who were inducted are considered to either relapse or be censored.  This creates 
new weights that can be applied to the Cox model, giving us the risk of relapse as though 
everyone had remained in the study until the end of treatment and the induction for both groups 
had been 100%. 
 
3.3.4.4 Restricted mean time 
 Since the induction rates vary between treatments, the mean time spent in treatment was 
also summarized for each treatment.  Time spent in treatment is defined as the date of induction 
until the date of relapse.  We want to evaluate relapse between treatment groups once an 
individual has actually been on the treatment in order to understand the impact of treatment.  
Individuals who were not inducted into the study were censored on their failed induction date for 
both induction status and relapse status.  The probability of being in treatment is estimated for 
each treatment arm x (65), following equation: 
 
𝐺! 𝑡 = 𝑆!! 𝑡 − 𝑆!! 𝑡 ,      (3.10) 
 
where 𝑆!! 𝑡  is the product-limit estimator of the Kaplan-Meier survival function for relapse for 
the specified treatment arm and 𝑆!! 𝑡  is the survival function for induction for the specified 
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treatment arm.  The mean time spent between induction and relapse over 274 days for each of the 





 To mitigate bias due to differential censoring, the three different censoring weighting 
techniques presented in section 3.3.4.1.1 were used.  In Model 1, inducted individuals were 
censored if they did not experience a relapse event.  There were no censored individuals who 
failed induction in Model 1 since all the failed inductees relapsed at some point during the study.  
However, when we apply the censoring weights to this model, we can see in Table 3.3 there is 
little difference between this method and the ITT approach, resulting in the risk of relapse as 
1.40 (1.13, 1.73) times as high with XR-NTX than with BUP-NX.  The similarity in results is 
due to the fact that the proportions of those who are censored do not vary between treatment 
groups, once they are inducted. 
 Therefore, additional considerations can be made, such as considering the failed 
inductees who failed induction due to relapse as relapse events, but considering the failed 
inductees who did so for other reasons as censored, as in Model 2 (Table 3.3).  This could 
provide a more accurate portrayal of the situation at hand, as relapse could be a factor of 
treatment arm before one is inducted.  There is a statistically significant 27% increase in the risk 
of relapse with XR-NTX compared to BUP-NX when we censor failed inductees who were not 
inducted due to reasons other than relapse (p=0.04).   
It is known that XR-NTX is harder into which to induct, and therefore censoring all failed 
inductees would weight them to account for this.  In Model 3 the risk of relapse is 1.15 times as 
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high with BUP-NX than with XR-NTX (p=0.27).  Results from Model 3 are similar to a PP 
approach where all failed inductees are excluded from the analysis.  
 
3.4.2 IPIW 
 Although censoring all failed inductees and then applying IPCW should give a less 
biased result than an unweighted model because it adjusts for confounders, it does not accurately 
account for the differential induction.  In order to weight observations to account for differential 
induction status and timing, we can apply IPIW.  In the X:BOT study there is differential 
induction between treatment groups, therefore IPIW provides an ideal way to address this.  These 
weights will account for the impact of relapse while on treatment by only considering relapses of 
those who are truly on the treatment and censoring all failed inductees on their failed induction 
date.  Using IPIW we can see in Table 3.3 there is a non-significant 11% decrease in the risk of 
opioid relapse (HR=0.89, 95% CI: 0.69, 1.14) with XR-NTX relative to relapse with BUP-NX 
when we account for differential induction between treatment arms. 
 
3.4.2 IPCW and IPIW 
 In order to create the ideal substance abuse RCT where everyone had been compliant and 
successfully inducted into the study at a standardized induction time with no loss to follow-up, 
we propose using the weights created from the IPCW and IPIW methods simultaneously.  Using 
Equation 3.9 we can create a new weight, 𝜛!", by multiplying the censoring weights and 
induction weights together.  This allows us to account for differential censoring, as well as 






































































































































































































































































































































































































































































































































































































































there is a non-significant 11% (HR=0.89; 95% CI: 0.69, 1.15) decrease in the risk of opioid 
relapse with XR-NTX relative to BUP-NX when we account for differential censoring and 
differential induction at the same time (p=0.36). 
 
3.4.4 Restricted mean time 
Over the 274 days of the study, including follow-up, there were 94% inducted into the BUP-
NTX treatment group and 72% inducted into the XR-NTX treatment group.  Out of those 
individuals inducted, 145 (51%) relapsed in the BUP-NX group and 101 (50%) relapsed in the 
XR-NTX group.  Figure 3.1 displays the restricted mean time spent in treatment.  XR-NTX has a 
mean time in treatment until relapse of 97 (72, 123) days and BUP-NX has a mean time in 
treatment until relapse of 126 (108, 143) days, indicating a difference of 29 (3, 54) days between 
treatment groups.  Figure 3.2 shows the probability of being in treatment before relapse for both 
treatment groups, indicating favored results for BUP-NX throughout the majority of the study. 
 
Figure 3.1. Survival curves for time to induction and time to relapse with restricted mean time 







Figure 3.2. Probability of induction for naltrexone (XR-NTX) (n=283) and buprenorphine-

















Maintaining balance between treatment groups is a key component of RCTs.  If non-
adherence is high, as in many substance abuse trials, randomization may be compromised, 
specifically if non-adherence is higher in one group.  Analyzing the data using an ITT approach 
allows us to use all the randomized individuals maintaining comparability between treatment 
groups from randomization (11).  One additional way to address loss to follow up is by using 
IPCW, which was applied to Models 1 – 3.  If we consider as relapses the failed inductees who 
were not inducted due to relapse, then our hazard ratio results are similar to an unweighted ITT 
approach.  If we consider failed inductees who were not inducted due to relapse as censored then 
our results are closer to an unweighted PP approach. 
In substance abuse trials there is a unique situation involving induction such that 
individuals must go through a designated detoxification process, dependent on the kind of 
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treatment they are expected to receive.  If the detoxification process is more of a challenge for 
one type of treatment (e.g., antagonist versus agonist) then this should be accounted for in the 
statistical analysis of the clinical trial.  Currently, there are no known statistical methods being 
used to account for differential induction in substance abuse trials. 
We propose a way to adjust for the effects of imbalance due to treatment induction is to 
use IPIW, as it may reduce bias in the X:BOT RCT.  This application allows us to analyze the 
data considering what would happen if everyone had been inducted into the study and received 
the randomized treatment.  Although the results using IPIW are similar to a PP approach without 
weighting, using a weighted Cox model offers a better and likely more accurate representation of 
the treatment effect.   
There are also benefits to using IPIW over a PP approach, such that sample size is 
preserved when using IPIW as we are able to use all individuals in the analysis, and therefore 
statistical power is maintained.  Limitations of using IPIW include the assumption that all 
confounders are observed.  We have accounted for several potential confounders in our weights 
(Equation 3.7), but this does not mean that we have guaranteed this assumption has been met, 
which could cause potential bias on our estimate (53). 
If we want to create the hypothetical idealized scenario where all individuals had been 
inducted and there had been no loss to follow-up, then using 𝜛!" weights that use both IPIW and 
IPCW are recommended.  In future substance abuse RCTs we propose the optimal analysis 




CHAPTER 4: A TUTORIAL ON THE USE OF INVERSE PROBABILITY OF 




Inverse probability weighting (IPW) is a method that weights specified observations and 
reduces bias when non-adherence or missing data is prevalent.  Two IPW techniques currently 
available are inverse probability of treatment weighting (IPTW) and inverse probability of 
censoring weighting (IPCW).  IPW methods have successfully been used in human 
immunodeficiency virus (HIV) and acquired immunodeficiency syndrome (AIDS) research to 
account for non-adherence, but have not been widely used in opioid use disorder (OUD) 
research.  However, there are benefits to initiating this approach with OUD randomized 
controlled trial (RCT) data since attrition and an inability to establish treatment therapy are often 
high in these studies.   
 An IPW approach seems optimal for substance abuse data as it would allow us to 
weight for non-adherence and control for bias of confounders (53), but IPTW and IPCW do not 
fully account for the problem in differential induction between treatment groups.  Induction is a 
term used in substance abuse studies to define the status at any given time that an individual has 
initiated treatment after randomization.  Therefore, our new IPW approach, deemed inverse 
probability of induction weighting (IPIW), is outlined in this tutorial such that observations will 
be weighted based upon time-varying induction status in order to reduce bias in the estimates of
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the treatment effect.  While IPW methods could in principle be applied to many statistical 
models, this tutorial focuses on the application of IPIW to Cox models. 
 
4.2 Motivating Example 
This tutorial will use publicly available data files from the X:BOT study (45) to instruct 
researchers how to create and apply inverse probability of induction weights in time-to-event 
analysis.  X:BOT is a comparative effectiveness randomized multi-center clinical trial that was 
conducted to compare the treatments of buprenorphine-naloxone (BUP-NX) versus injectable 
extended-release naltrexone (XR-NTX) in 570 patients.  BUP-NX and XR-NTX are two U.S. 
Food and Drug (FDA) approved medications that have been shown to be highly effective at 
treating OUD.  
This tutorial will focus on time to relapse, but these methods can be applied to any data 
such that patients initiate treatment (or an occurrence of an event) at varying times post-
randomization and are followed over time until the occurrence of a specified outcome or 
censoring occurs.  Research areas that IPIW can be applied include substance abuse, HIV/AIDS, 
fertility treatment, as well as many other fields of research.  
Previously, in Chapter 3, IPW methods regarding efficacy of time to relapse were 
conducted.  IPIW was introduced using the X:BOT data to account for differential induction 
between treatment groups and to mitigate bias in hazard ratio estimation of opioid relapse in Cox 
models.  This tutorial will outline the steps to create and apply the induction weights using the 




4.3 Methods  
4.3.1 Notations and Definitions 
IPIW is a novel application of IPW created specifically for substance abuse clinical trials 
where the induction proportions vary between treatment groups or the induction failure is 
sufficiently high to cause non-negligible treatment effect bias if ignored.  Induction is a term 
used in substance abuse studies to define the status that an individual has started taking a 
treatment after randomization.  The term does not indicate that an individual has successfully 
gone through treatment, only that they have been administered at least one dose of the assigned 
treatment.  Induction failure refers to when a trial participant never receives an effective course 
of treatment. Statistically, this is in essence the situation in which their censoring time or relapse 
failure time is less than their (unobserved) induction time.   
In the X:BOT study, induction failure occurred in 96 individuals when one of the 
following criteria was met: failed naloxone challenge (1%), left prior to induction (6%), rejected 
treatment (24%), met criteria for relapse (68%), reached end of induction window (1%).  IPIW is 
an approach that will help analyze data where induction into one treatment group is substantially 
more challenging than for the other group, resulting in higher induction failure proportions.  The 
problem addressed by IPIW is different from IPTW such that the covariate distributions may not 
greatly differ between treatment groups, but rather that individuals are less likely to be inducted 
into one treatment group over the other for an array of reasons, depending on the study at 
hand.  IPIW will create weights for the inverse probability of induction with the aim to produce 
asymptotically unbiased estimates of treatment effect.  Simulations will be used (see Appendix) 
to demonstrate that the novel weighting methods give unbiased results as expected. 
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The analyses of interest involve application of the Cox proportional hazards model (48) 
for the purpose of analyzing censored failure times.  At the time of their introduction, life tables 
were extensively used, and these models provided a more formal statistical theoretical approach 
that extended the work that Kaplan and Meier had done in regards to life tables.  The method 
considers each individual in a study as either time to “failure” or time to “loss” (censoring) such 
that the time to failure is greater than time to censoring (48).  Therefore, for continuous failure 
time, T, the survivor function and hazard failure rate are represented respectively as:  
 
     𝐹 𝑡 = 𝑃 𝑇 ≥ 𝑡       (4.1) 
  
     𝜆 𝑡 = lim∆!→!!
!(!!!!!!∆!|!!!)
∆!
    (4.2) 
 
Cox proportional hazards regression is a common statistical technique used in time-to-
event analysis.  It has the ability to adjust for several risk factors or exposure with respect to 
survival time in order to measure the hazard rate, or instantaneous risk of failure, given that an 
individual has survived up to that time (49).  Therefore, in order to assess the relation between 
the distribution of failure time and covariates, z, the hazard can be modeled as: 
 
     𝜆 𝑡; 𝒛 = exp 𝒛𝜷 𝜆!(𝑡)     (4.3) 
 
where z is a 1×𝑝 vector of measurements, 𝜷 is a 𝑝×1 vector of unknown parameters and 𝜆!(𝑡) is 
an unknown baseline hazard function given the hazard function for the standard set of conditions 
z=0 such that the predictors have a proportional effect on the predicted hazard.  This model 
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assumes nothing about the shape of the baseline hazard function, but does make assumptions on 
independence, proportionality of hazards over time, and a linear association between predictors 
and the natural logarithm of the relative hazard.  It is considered a semi-parametric model.   
In order to apply the induction weights to a Cox model, we first need to define the 
weights:  
    𝜔!" =  𝜔!"#
!
!!! =
! !!"!! !! 
! !!"!! !!,!!"!!
!
!!!     (4.4) 
 
such that 𝜔!"  is the inverse probability of induction weight for patient i on day j; 𝜃 is an indicator 
variable such that 𝐼!" = 0 indicates that individual i has yet to be inducted into the study before 
day j and 𝐼!" = 1 indicates otherwise;  𝑋! = 1 indicates individual i was randomized to XR-NTX 
and 𝑋! = 0 indicates individual i was randomized to BUP-NX; and 𝑉!"!! is defined as a vector 
of time-fixed and time-varying covariates.  More specifically, the weight 𝜔!"# is proportional to 
the inverse probability the i-th individual is inducted into the study on day j conditional that they 
have not been inducted through day j-1.  In turn, the weight 𝜔!" is proportional to the cumulative 
inverse probability the individual has not been inducted into the study through day j-1.  Once 
individuals have been inducted into the study, they are assigned a weight of 1.   
The numerator of the induction weights indicates the conditional probability of remaining 
not-inducted as a function of treatment arm and time: 
 
     𝑃 𝐼!" = 𝜃 𝑋!                                             (4.5) 
 
The denominator of the induction weights indicates the conditional probability of 
remaining not-inducted as function of time-fixed and time-varying covariates: 
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     𝑃 𝐼!" = 𝜃 𝑋! ,𝑉!"!!          (4.6) 
 
We can apply the induction weights to a Cox proportional hazards model to obtain partial 
likelihood estimates of 𝜷 using IPIW.  The use of partial likelihood allows a likelihood 
estimation that can be calculated without knowledge of 𝜆!(𝑡), where 𝜆!(𝑡) is an unknown 
baseline function given the hazard function for a set of conditions such that the predictors have a 
proportional effect on the predicted hazard.  The partial likelihood is a product of the observed 
failure times of conditional probabilities of having the observed failure, given the risk set at that 
time: 




!!!       (4.7) 
 
where      𝑅 𝑡 = {𝑖 ∶ 𝑌! > 𝑡}      (4.8) 
 
is the risk set that represents the group of individuals who are at risk for failure time t and 𝑌! is 
the failure time for individual i.  Therefore, the application of IPIW to a Cox model implies that 
that the partial likelihood is:  
 




!!!      (4.9) 
 
Conceptually, the use of induction weights in Cox proportional hazards models will allow 
us to estimate the counterfactual risk of relapse in which induction failure was identical in both 
arms with a common distribution of time to induction.  
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4.3.2 Outcomes 
 In this analysis we use a Cox proportional hazards model with time to relapse as the 
outcome.  Time to relapse is defined as opioid use measured from the date of randomization (day 
0).  The Cox proportional hazards model will be weighted using IPIW.  In order to create the 
induction weights we will also define logistic regression to model the logit a participant has yet 
to be inducted.   
 
4.3.3 Variable selection 
The first step for calculating the denominator of the induction weights is to consider all 
predictors of relapse and induction separately.  In order to assess this with the X:BOT data we 
considered all of the baseline characteristics Lee et al. (44) included in their Table 1 that were 
available in the publicly available data files (45), as well as any additional baseline covariates we 
thought could have impact on relapse or induction.  The additional covariates in Table 3.1 were 
chosen based on prior knowledge of risk factors for induction and relapse.  These characteristics 
(Table 3.1) included: gender, age, race/ethnicity, intravenous drug use, primary opioid used in 
the seven days before detoxification admission, age at onset of opioid use, duration of opioid use, 
substance use over past 30 days, Hamilton Rating Score, psychotic episode history, psychiatric 
disorder history, and the Opiate Withdrawal Scale.   
Race/ethnicity was created from the original dataset to encompass three categories: 
Black, Hispanic, and White/other.  The original dataset consisted of individuals specified as one 
or more races.  For the purpose of finding predictors of relapse and induction, a derived race 
variable was created such that each individual only fell into one race category: anyone who had 
identified as Black was considered Black, regardless of mixed race (n=73); individuals who 
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specified they were Hispanic and White were considered Hispanic (n=93); all other races (n=17) 
were included with White individuals (n=387). 
Intravenous drug use, primary opioid used in the seven days before detoxification 
admission, psychotic episode history, and psychiatric disorder history were coded as binary 
variables.  Primary opioid used in the seven days before detoxification admission was considered 
as buprenorphine, opioid analgesics, and methadone versus heroin.  Psychiatric disorder history 
included anxiety, ADHD, bipolar, major depressive disorder, schizophrenia, suicidal ideation, 
suicidal behavior, homicidal, and other psychiatric history.  If an individual had any of the 
aforementioned disorders then they were considered to have a psychiatric disorder history. 
Four types of substances were considered for substance use over the past 30 days from 
baseline, which included binary variables of alcohol intoxication, cannabis, stimulants 
(amphetamine, methamphetamine, and/or cocaine), and sedatives (barbiturates and/or sedative 
hypnotic tranquilizers). 
Age, age at onset of opioid use, duration of opioid use, Hamilton Rating Score, and 
Opiate Withdrawal Scale were considered continuous variables to begin with such that the mean, 
standard deviation, interquartile range, 25th percentile, and 75th percentile were found for each.  
The age at onset of opioid use was the minimum age of onset for heroin, methadone, or opiates 
reported.  The duration of opioid use was the total number of years using heroin, methadone, or 
opiates.  The Hamilton Rating Score was a total score from several questions about depressed 
mood, guilt, suicide, insomnia, anxiety, weight loss, etc. (66).  A lower score indicates an 
absence of depressive symptoms and a higher score indicates moderate severity of depressive 
symptoms.  The Opiate Withdrawal Scale was a scale from 0 to 10 that described how 
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uncomfortable the patient’s opioid withdrawal was such that 0 represented none and 10 
represented almost unbearable. 
  Each of the above variables was analyzed initially separately using an unweighted Cox 
model for the hazard ratio of relapse, with treatment as the sole explanatory variable.  A logistic 
regression model for participant-time observations as described in detail further below was also 
created for each variable separately in order to calculate its effect on the logit for not being 
inducted (versus inducted), also with treatment as the sole explanatory variable.  The 
interquartile range was used to quantify the uncertainty of the estimated hazard ratio and odds 
ratio for all continuous variables for interpretation purposes.  The predictors for the induction 
weights were chosen based on criteria of predetermined p-value of not exceeding 0.20 or a 
hazard ratio or odds ratio less than 0.75 or greater than 1.33.  Using these criteria allows us to 
determine predictors with a meaningful association to relapse and/or induction.  We found race, 
primary opioid used in the seven days before detoxification admission, substance use over the 
past 30 days from baseline of alcohol intoxication and cannabis, psychiatric disorder history, and 
Opiate Withdrawal Scale to all fit the criteria for odds of not being inducted (Table 3.1).  
However, only race, primary opioid used in the seven days before detoxification admission, and 
Opiate Withdrawal Scale (categorical) fit the criteria for both hazard ratio of relapse and odds 
ratio of not being inducted and therefore, only those three variables were included in the 
induction weights.  Although including covariates that fit the criteria for both hazard ratio of 
relapse and odds ratio of not being inducted is not a requirement for creating weights, it is 
common practice to select explanatory variables that fit both criteria (55). 
  Age and the Opiate Withdrawal Scale were also analyzed using categorical variables to 
determine if continuous variables could be used in this analysis.  Age and Opiate Withdrawal 
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Scale were categorized by quartiles to create categorical variables.  Age was separated into 
groups of less than or equal to 26, 27 to 31, 32 to 39, and greater than 39 years old.  The Opiate 
Withdrawal Scale was categorized into groups that consisted of less than or equal to five, six to 
seven, eight to nine, and ten.  The hazard of relapse and odds of induction were then found for 
each of the categorized groups for both age and Opiate Withdrawal Scale variables.  The Opiate 
Withdrawal Scale hazard of relapse increased linearly as the withdrawal scale increased and odds 
of not being inducted decreased linearly as the scale increased, therefore a continuous variable 
was used for this analysis.  Age did not appear to have a linear effect: the hazard ratio of relapse 
increased from 27 – 31 years to 32 – 39 years, but then decreased for individuals over 40 years of 
age.  The odds of not being inducted decreased from 27 – 31 years to 32 – 39 years, but 
increased for individuals over 40 years of age.  Therefore, these age groups were included as a 
categorical variable for the induction weights. 
It is preferable to include as many covariates as reasonably possible in the logistic 
regression model (Equation 4.6) to control for bias from confounders (53).  Parsimony is not the 
intended goal, but overfitting relative to the sample size and what the sample size would support 
should be avoided.   
 
4.4 Datasets 
Several of the publicly available data files (45) were compiled to create a dataset with the 
relevant information necessary to create induction weights.  The compiled dataset will include 
variables such as treatment assignment, baseline characteristics, relapse status, and induction 
status, shown in Table 4.1.  Description of the variables can be found in Table 4.2. 
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To apply the IPIW method to a Cox model, we create two separate datasets.  The first 
dataset is for the creation of induction weights, which includes a time-varying induction status 
variable (OUTCOME).  The second dataset includes a time-varying relapse status 
(RELAPSE_OUTCOME).  The two datasets will not have the same number of rows, as the days to 
induction (or not inducted) is less than or equal to the days to relapse or censored. The dataset for 
creating induction weights contains multiple observations per participant with a dichotomous 
time-varying outcome of induction versus not (OUTCOME).  The first observation for each patient 
starting with day=0 to indicate the time of randomization with the remaining observations for 
each participant determined from participant-level variables for ever having been inducted 
(INDUCTION=1 if yes, and INDUCTION=0 if no) and for number of days until induction (or 
induction failure) called INDUCTION_TIME.  Individuals who are not inducted are censored on 
their failed induction day.   
The number of rows for a participant will increase on a daily basis, starting from 
randomization (day 0) until the day of their induction or induction failure (day j).  The OUTCOME 
variable indicates the time-varying induction status such that OUTCOME=0 indicates an 
individual has not yet been inducted and OUTCOME=1 indicates an individual has been inducted 
on day j.  For inducted individuals, the time-varying induction status will remain “0” up to day    
(j–1), such that the time-varying induction status changes to “1” on day j.  Once an individual 
has been inducted, there are no further observations for that individual.  For individuals who 
were not inducted into the study, their time-varying induction status will remain “0” for all of 
their observations. Each individual will have (j+1) rows in the induction dataset.   
The date of induction or induction failure was found in the public data files.  The date of 
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Table 4.2. Variable descriptions used in the tutorial  



















weight of not 
being inducted 
through day j-1 
X     X 
CNUM 
Numerator for the 
conditional 
weight of not 
being inducted 
through day j-1 
X     X 





X     X 
DISPENSE_TIME 
Day of first 
injection (XR-
NTX) or first 
dose dispensed 
(BUP-NX) 
 X X   X 
GENDER Gender of participant  X X   X 
INDUCT_TIME 
Day of induction 
or induction 
failure 
  X X  X 
INDUCTION Induction status  X X X  X 
INFAILDT Induction fail date  X X   X 
IW Induction weights X     X 
NUMER 
Numerator for the 
cumulative 
induction weights 
X     X 
OUTCOME Induction status X   X  X 
PATID Patient ID  X X X X X 
RACE Race/ethnicity of participant  X X   X 
RELAPSE 
Relapse status 




  X  X X 
RELAPSE_OUTCOME Relapse status X    X X 
RELAPSE_TIME Day of relapse or censoring   X  X X 
TRTSHOWN Treatment group  X X X X X 
XRPASMDT Day of relapse assessment  X X   X 
XRRELAPS Relapse status  X X   X 
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induction was specified in the data files.  If that date was missing, the date of first medication 
dispensed for BUP-NX was used.  The variable DISPENSE_DATE indicates the date of first 
injection or date of first medication dispensed for XR-NTX and BUP-NX, respectively. The last 
recorded date of censoring for individuals in the X:BOT dataset was day 274. Using a SAS 
DATA step, the following code is used to create the induction dataset: 
 
data induction; 
do day=0 to 274;  
   
if day=induction_time then do; 





if day<=induction_time then output;  
end; 
run; 
Table 4.3 displays the 11 rows of the induction dataset for PATID = 109876, who was 
inducted into XR-NTX 10 days after randomization. 
 
Table 4.3 Data rows for the induction dataset for patient ID 109876  
PATID TRTSHOWN INDUCTION INDUCTION_TIME DAY OUTCOME 
109876 XR-NTX 1 10 0 0 
109876 XR-NTX 1 10 1 0 
109876 XR-NTX 1 10 2 0 
109876 XR-NTX 1 10 3 0 
109876 XR-NTX 1 10 4 0 
109876 XR-NTX 1 10 5 0 
109876 XR-NTX 1 10 6 0 
109876 XR-NTX 1 10 7 0 
109876 XR-NTX 1 10 8 0 
109876 XR-NTX 1 10 9 0 
109876 XR-NTX 1 10 10 1 
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A second dataset is created to indicate a time-varying time to relapse.  This dataset will 
include more rows than the induction dataset since time to relapse or censored is greater than 
time to induction.  The relapse dataset will include a row for each individual for each day, 
starting with randomization (i.e., day 0) until the day of relapse or censoring, where the 
XRRELAPS variable from the publicly available data file (45) was used to determine relapse 
status.  Therefore, a new variable, RELAPSE, was created to indicate relapse status, as well as a 
new relapse/censoring day variable, RELAPSE_TIME, which indicates the day of relapse or 
censoring for inducted individuals and the day of censoring for individuals not inducted into the 
study.  Individuals not inducted into the study will have RELAPSE_TIME = INDUCT_TIME, 
as they are censored on their failed induction day.  Each individual will have their number of 
rows equal to (RELAPSE_TIME + 1) in the relapse dataset.  Example SAS code to create the 
relapse dataset is shown below: 
 
data relapse; 
do day=0 to 274;  
 
if day=relapse_time then do; 








Table 4.4 displays only the last 10 rows of the relapse dataset for PATID = 109876, 
who relapsed 135 days after randomization where RELAPSE_TIME indicates the day of relapse.  
Note that for PATID = 109876, there are 136 rows in the relapse dataset. 
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Table 4.4. Partial listing of data rows for the relapse dataset for patient ID 109876  
PATID TRTSHOWN RELAPSE RELAPSE_TIME DAY RELAPSE_OUTCOME 
109876 XR-NTX 1 135 126 0 
109876 XR-NTX 1 135 127 0 
109876 XR-NTX 1 135 128 0 
109876 XR-NTX 1 135 129 0 
109876 XR-NTX 1 135 130 0 
109876 XR-NTX 1 135 131 0 
109876 XR-NTX 1 135 132 0 
109876 XR-NTX 1 135 133 0 
109876 XR-NTX 1 135 134 0 
109876 XR-NTX 1 135 135 1 
 
 
 4.5 Logistic regression models 
Creating induction weights requires fitting two logistic regression models: one for the 
numerator of the induction weights and one for the denominator of the induction weights.  The 
induction dataset with the time-varying induction status is then analyzed with logistic regression 
models to create the induction weights.  The denominator of the induction weights was created 
using logistic regression to model the conditional probability of remaining not inducted as a 
function of 𝑉!"!!, which included continuous time (in days), race, primary opioid used in the 
seven days before detoxification admission, Opiate Withdrawal Scale, treatment, and the 
interaction of time and each of those covariates to account for any heterogeneous effect across 
time: 
 
  logit 𝑃 𝐼!" = 𝜃 𝑋! ,𝑉!"!! =  𝛾! + 𝛾!𝑋! + 𝛾!!𝑉!"!!    (4.10) 
 
In SAS 9.4, the following code outputs the results for the denominator. 
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proc logistic data = induction; 
 class trtshown(ref='BUP-NX')  race(ref='1')  /*Race 1=White, 2=Hispanic 
3=Black*/ 
  drugchoice(ref="Heroin"); 
 
 model outcome(event='0') =  trtshown race drugchoice  
  mhopiwdl day trtshown*day race*day drugchoice*day mhopiwdl*day; 
 
 ods output parameterestimates; 
 output out=cenden p=cden;  
run; 
 
This analysis produced estimates (CDEN) of the denominator of the induction weights, 
𝜔!"#, for each individual on each day of the study until they were either inducted or failed 
induction.   
The numerator of the induction weights was created using logistic regression to model 
the conditional probability of remaining not inducted as a function treatment and time: 
 
  logit 𝑃 𝐼!" = 𝜃 𝑋!  = 𝛿! + 𝛿!𝑋! + 𝛿! 𝑡𝑖𝑚𝑒! + 𝛿! 𝑡𝑖𝑚𝑒! 𝑋!   (4.11) 
 
In SAS 9.4, the following code was created, which outputs the results for the numerator: 
 
proc logistic data = induction; 
 class trtshown(ref='BUP-NX') ; 
 model outcome(event='0') = trtshown day trtshown*day; 
 ods output parameterestimates; 
 output out=cennum p = cnum; 
run; 
 
This analysis produced estimates (CNUM) of the numerator of the induction weights, 𝜔!"#, 
for each individual on each day of the study until they were either inducted or failed induction.   
	 77	
The numerator (CENUM) and denominator (CENDEN) datasets from the separate logistic 
regression predicted probabilities are then merged together (dataset NUM) by PATID and DAY, 
creating an estimate of the numerator and denominator of the induction weights for every 
individual for every day until their day of induction or day of failed induction.  The conditional 
weights, 𝜔!"#, are created by taking the ratio of the numerator and denominator estimates for 
each individual on each day such that each individual had a different induction weight for each 
day of the study until day of induction or failed induction.  Next, the conditional weights are 
multiplied together to create 𝜔!", the cumulative weights, for each individual, as specified in 




by patid day; 
 retain denom numer; 
 if first.patid then do; 
  denom = 1; numer=1; 
 end; 
 denom = cden*denom; 
 numer = cnum*numer; 





This SAS codes produces a dataset with (j + 1) rows for each individual such that the 
cumulative sums are produced as IW for each day until induction or failed induction for each 
individual.  This dataset can then be merged with the relapse dataset by PATID and DAY.   
Once an individual was inducted to the study, the induction weight should be set to 1 for 
the remaining days until they either relapsed or were censored, as no weight should be given 
once an individual is inducted.  Individuals who were not inducted were censored on the date of 
failed induction and will receive a weight for every day from randomization until the day they 
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are censored.  Table 4.5 displays the induction weights data for PATID = 109876 for the first 
15 days since randomization and the last five days until relapse on day 135.  Table 4.6 displays 
the induction weights data for an individual who failed induction on day 5 and therefore was 
censored for relapse (RELAPSE_OUTCOME = 0) on that same day.  
Using an unadjusted Cox model we apply induction weights to account for the 
differential induction proportions between treatment groups and compute the hazard ratio of 
relapse comparing treatments.  A WEIGHT statement should be added in the PROC PHREG 
syntax to incorporate the censoring weights.  The COV(AGGREGATE) statement calculates the 
robust sandwich estimate of the covariance matrix such that the score residuals are aggregated 
over identical PATID (67).  Since there are multiple rows for each individual and the weights are 
changing for each individual for each day, two time variables are used to account for the time-
varying relapse outcome.  In unweighted Cox models, a constant date of the event is used to 
account for the outcome.  However, in order to incorporate a changing induction weight over 
time, two new variables are created for each individual such that the variable IN starts at day -1 
and ends of the day prior to censoring or relapse.  The variable OUT starts on day 0 and ends on 
the day of censoring or relapse for each individual (Table 4.7).  These two variables are then 




 in = day-1; 
 out = min(day, relapse_date); 
run; 
proc phreg data = inout covs(aggregate); 
 id patid; 
 weight cw; 
 class trtshown(ref="BUP-NX"); 
 model (in,out)*relapse_outcome(0) = trtshown / rl ties=efron; 
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Table 4.8. Inverse probability of induction weighting Cox model results for hazard of relapse 








95% Hazard Ratio 
Confidence Limits 
XR-NTX vs. BUP-NX  -0.12 0.13 0.352 0.89 0.69 1.14 
 
 
4.6 Sensitivity analysis 
Since IPIW is a novel application of IPW methods, a sensitivity analysis was performed 
in order to provide assessment of the validity of the IPIW technique.  The weights of IPW 
methods should center around the value of 1, therefore a boxplot (Figure 4.1) was generated to 
display the induction weights and assures the weights were created properly.  When the 
induction weights were created the weights varied from a value of 0.51 to 2.73.  The boxplot of 
the induction weights (Figure 4.1) shows some outliers above the weight of 2.  Therefore, in 
order to see which group was causing the higher weights, the mean, 99th percentile, and 
maximum value of the weights were found for the inducted group and the group that failed to be 
inducted, separately.  For the inducted group, the 99th percentile was 1.83 with a maximum value 
of 2.73 and mean of 1.02.   The failed inductee group had a 99th percentile of 1.89 with a 
maximum value of 1.89 and mean of 1.06.  Therefore, weights were truncated at 2.0 to see if the 
weights greater than this value from the inducted group were unduly influencing the hazard ratio 
results.  The Cox model was rerun as specified in the IPIW analysis with the only change of 
capping these weights.  This analysis resulted in a hazard ratio of 0.89 for XR-NTX compared to 
BUP-NX with a 95% confidence interval of (0.69, 1.14), indicating that from these results, we do 





Figure 4.1. Boxplot of induction weights 
 
4.7. Discussion 
The public available X:BOT data provides an exemplar for why induction weights should 
be applied to a statistical model, due to differential timing, as well as proportions, of induction 
between treatment groups.  However, some pitfalls with analyzing any clinical trial dataset 
include the quality control of the data, which is sometimes beyond the investigator’s control.  
Confirming and reanalyzing reported results from publicly available data could also be a 
challenge.  Communication with the lead principal investigator and statistician from the original 
study is useful to confirm data discrepancies.  
 Despite these challenges, we were able to compile a working dataset to introduce how to 
create induction weights, which can be used to account for differential induction between 
treatment arms.  There are three scenarios in which induction weights are useful to apply to a 
statistical model: 
 











2. Induction timing varies greatly between treatment arms 
3. Induction proportions and timing varies greatly between treatment arms 
 
In the X:BOT data we use the induction weights to account for both differential 
proportions and timing.  The weights allow us to give a relatively larger weight to individuals 
who are inducted early on into XR-NTX than individuals who inducted in the BUP-NX group, as 
there is a higher failed induction proportion in XR-NTX.  The time to induction is also longer on 
average for individuals in the XR-NTX group.  When induction weights are applied to a Cox 
model, they create an idealized scenario such that everyone was conceptually inducted at a 
standardized induction time. 
 The induction weights can be applied to a large scope of research areas.  Induction 
weights are useful in substance abuse RCTs when the treatments compared differ in one or more 
ways.  For instance, the X:BOT study compared two treatments that differed in the detoxification 
process, treatment form, and treatment dispense timing.  The detoxification process was most 
critical for induction status, as it determined whether a participant would receive the first dose of 
medication.  The XR-NTX group had a greater challenge with detoxification, due to its 
antagonist properties, therefore resulting in a longer time until induction and a lower proportion 
of inducted individuals compared to BUP-NX.  IPIW allows us to adjust for the effects of 
induction imbalance. 
The weights can also be applied to broader fields beyond substance abuse, such as 
HIV/AIDS.  In this field, the time to rebound is weighted by the probability of suppression where 
“suppression” refers to a status such that a patient’s viral load is undetectable and “rebound” 
occurs if the viral load becomes detectable after suppression.  Induction weights can also be used 
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for any other RCTs that model suppression and rebound to determine treatment efficacy, such as 
hepatitis or any chronic viral infection (68).  Additionally, this technique can also be applied to 
fertility research, where time to conception is weighted by the probability of initiating fertility 
treatment.  Induction weights could be particularly useful if fertility treatments vary in method 
(oral, injection, surgical) and/or patient side-effects.   
Induction weights allow models to account for differential initiation of an event that has 
an assumed profound effect on the outcome  (e.g. induction to relapse, suppression to rebound, 
fertility to conception).  The weights in this tutorial were applied to a Cox model to allow us to 
calculate a hazard ratio estimate of treatment with reduced bias as though all patients in the trial 















CHAPTER 5: DISCUSSION 
 
This dissertation addressed challenges commonly found in substance abuse randomized 
controlled trials (RCTs) and focused on the application of inverse probability weighting (IPW) 
methods to Cox models.  This was a secondary analysis to the X:BOT study to assess opioid 
relapse, positive opioid urine tests, and overdose in individuals randomized to injectable 
extended-release naltrexone (XR-NTX) and buprenorphine-naloxone (BUP-NX).  Replication of 
analyses using publicly funded and available clinical trial data are a critical tool for generating 
confidence in major trials. This dissertation evaluated the safety and efficacy results claimed by 
Lee et al. (44) by examining the risk of relapse, risk of first positive opioid urine test, and risk of 
overdose during pre-treatment, treatment, and follow-up. Two accepted statistical approaches, 
intention-to-treat (ITT) and per-protocol (PP), were used to probe the impact of high induction 
failure early in the study in the XR-NTX group (28%), compared to BUP-NX (6%).  Induction is 
a term used in substance abuse studies to define the status that an individual has started taking a 
treatment after randomization.  Induction failure refers to when a trial participant is never 
inducted and never receives a dose of treatment, therefore leaving the study.  Induction failure in 
the X:BOT study is high and is a marked problem in other naltrexone trials as well.  
Since an ITT approach is typically considered to be a more conservative approach than a 
PP approach in a superiority trial, it is generally the method used for a primary analysis to 
preserve balance between treatment arms.  When using an ITT approach, we can see the effect of  
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being in XR-NTX or BUP-NX, but bias is introduced if there is noncompliance (58).  A PP 
approach allows us to determine the effect of the two treatments and is not affected by partial 
adherence to the program, but is subject to selection bias (58).  The differential induction 
proportions in the two treatment groups may have compromised balance of randomization in the 
PP approach.  A way to control for the incomparability between the two groups would be to 
adjust for covariates in the model that are associated with nonadherence to treatment.  However, 
additional covariates were not included in the models in Chapter 2 in order to replicate the 
original approach taken by Lee et al. (44). 
Although PP allows us to analyze the data of only those patients who adhered to their 
treatment, it produces bias in our results for several reasons.  A PP approach violates the 
randomization principle that the two groups are equally comparable. A large induction failure in 
the XR-NTX group would indicate that the XR-NTX and BUP-NX groups are no longer 
balanced and this problem is only amplified as the number of individuals who dropped treatment 
over time increases (11).  Since patients who comply to treatment are different than those who do 
not adhere to treatment, results of a PP approach are only valid if drop out is assumed to occur 
completely at random (59).  However, in this study it cannot be assumed that induction failure is 
completely random, as the initiation of XR-NTX is presumably more difficult than BUP-NX due 
to the large percentage (28%) of individuals who were not inducted into the XR-NTX arm.  To 
reduce the problems that occur in a PP approach, an ITT approach is performed and ensures 
maintaining comparability between the two groups (11).  Due to the selection bias from a PP 
approach, ITT would be preferable when considering effectiveness outcomes in this trial.  The 
emphasis on the PP analysis in the original trial analysis (44) assessed only those patients who 
adhered to treatment, generating a form of selection bias.  Hernan et al. (58) suggests that if the 
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PP approach were to be used then there are three ways to produce valid results, which include 
censoring patients once they have stopped receiving the medication, not censoring patients who 
stop treatment due to clinical causes, and adjusting for confounding caused by incomplete 
adherence.  None of these approaches were used in the Lee et al. (44) analyses. 
If the results for the ITT and PP analyses differ considerably, further questions should be 
considered.  In this analysis, the hazard ratios of opioid relapse differ considerably for the ITT 
(HR: 1.40; 95% CI: 1.13, 1.73) and PP (HR: 0.89; 95% CI: 0.69, 1.14) approaches, resulting in 
conflicting conclusions.   
In contrast to opioid relapse, the results for positive opioid urine test and overdose events 
in this analysis did not differ for the ITT and PP approaches when the hazard ratio is averaged 
over the observation period.  Time-dependent Cox models were also analyzed due to the 
graphical violation of the proportional hazards assumption.  During treatment and follow-up, the 
risk of overdose is higher in XR-NTX compared to BUP-NX for both ITT and PP approaches, 
with statistically significant results during treatment.  During pre-treatment and follow-up 
individuals in the XR-NTX group have an increased risk for positive opioid urine compared to 
the BUP-NX group when using both ITT and PP approaches.  However, during treatment 
individuals in the BUP-NX group have an increased risk of positive opioid urine compared to the 
XR-NTX group.  When evaluating opioid relapse, there are major differences between the ITT 
and PP analyses.  During pre-treatment and treatment, the ITT approach indicates a higher risk 
of opioid relapse in the XR-NTX group compared to BUP-NX, but the PP approach indicates 
XR-NTX to have favorable results during treatment. 
The implications from Chapter 2 show that regardless of the analysis used, induction 
failure for the XR-NTX arm is high during the first three weeks, which may impact the ability to 
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draw accurate conclusions regarding treatment effectiveness.  Further research was necessary to 
adequately produce reduced biased estimates.  Therefore, various censoring techniques and 
induction weighting was introduced in Chapter 3, and summarized below. 
 Maintaining balance between treatment groups is a key component of RCT and IPW 
methods allows us to weight observations that will reduce bias from noncompliance.  IPW can be 
used when there is noncompliance in a study or when missing data is prevalent in order to reduce 
bias.  Currently IPW is commonly used for HIV data to account for high non-adherence but is 
not widely used in in opioid use disorder (OUD) clinical trials.  Substance abuse data is similar 
to HIV data in the respect that non-adherence is high.  Analyzing the X:BOT data using an ITT 
approach, as shown in Chapter 2, allows us to use all the randomized individuals maintaining 
comparability between treatment groups from randomization (11).  An additional way to address 
loss to follow up is by using an IPW method, such as inverse probability of censoring weighting 
(IPCW), where positive weights are created for the time prior to the date censored and weights of 
one are given to the time on or after censoring for each individual.  In Chapter 3 we produced 
three Cox models with various IPCW where failed inductees were either censored or considered 
relapses.  If we consider the failed inductees as relapses then our hazard ratio results (HR: 1.40; 
95% CI: 1.13, 1.73) are similar to an unweighted ITT approach.  If we consider failed inductees 
who were not inducted due to relapse as censored then our results (HR: 0.87; 95% CI: 0.67, 1.12) 
are closer to an unweighted PP approach. 
Although IPCW produced less biased results than an unweighted model, as it accounts 
for the differential censoring between treatment groups, it does not account for the differential 
induction between treatment groups.  In substance abuse trials there is a unique situation 
involving induction such that individuals must go through a designated detoxification process, 
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dependent on the kind of treatment they are expected to receive.  If the detoxification process is 
more of a challenge for one type of treatment (e.g., antagonist versus agonist) then this needs to 
be accounted for in the statistical analysis of the clinical trial.  Currently, there are no known 
existing statistical methods being used to account for differential induction in substance abuse 
trials. 
Therefore, a IPW method to adjust for the effects of the imbalance due to treatment 
induction, called inverse probability of induction weighting (IPIW) was proposed in Chapter 3. 
This application allows us to analyze the data considering what would happen if everyone had 
been inducted into the study and actually received the randomized treatment at a standardized 
induction time.  The results using IPIW (HR: 0.87; 95% CI: 0.67, 1.12) are similar to a PP 
approach without weighting.  However, using a weighted Cox model offers a better and likely 
more accurate representation of the treatment effect.  There are also benefits to using IPIW over 
a PP approach, such that sample size is preserved when using IPIW as we are able to use all 
individuals in the analysis, and therefore statistical power is maintained.   
Using an IPW method such as IPIW is used to generate a pseudo-population where 
induction and treatment are independent of one another.  We can also create the idealized 
scenario where all individuals had been conceptually inducted and there had been no loss to 
follow-up using both IPIW and IPCW.  These results (HR: 0.87; 95% CI: 0.68, 1.13) are similar 
to both the unweighted PP and IPIW approaches.   
 Computing induction weights, although similar to computing censoring weights, involves 
a more complex process and data structure.  Prior knowledge and research are necessary to 
determine which predictors to include in the induction weight calculations.  In Chapter 4 a 
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tutorial on how to generate induction weights in SAS 9.4 was created.  The induction weights are 
useful to apply to any statistical model when one of the three scenarios are present:  
 
1. Induction proportions vary greatly between treatment arms 
2. Induction timing varies greatly between treatment arms 
3. Induction proportions and timing varies greatly between treatment arms 
 
The X:BOT study is an example where induction weights can be used to account for both 
differential proportions and timing.  The X:BOT study has huge differences in induction between 
groups, but this is a common issue in substance abuse studies.  Sullivan (2017) reports induction 
to XR-NTX using different detoxification methods to be as low as 32.7% (69).  This implies that 
a critical component in induction status is the detoxification method, not per se the medication.   
For the X:BOT study, induction weights will allow us to correct this imbalance in 
induction status between treatment groups.  It gives higher weights to individuals who are 
inducted early on in the XR-NTX group than to individuals who inducted in the BUP-NX group, 
as there is a higher failed induction proportion in XR-NTX.  The weights create a conceptually 
idealized scenario such that everyone was inducted at a standardized induction time. 
 These weights are useful in substance abuse clinical trials when there is differential 
induction, but also applicable to a larger array of research areas.  For example, induction weights 
can be applied to HIV/AIDS data by weighting the probability of suppression with a time to 
rebound outcome.  Induction weights could be used for any other chronic viral infection clinical 
trials that model suppression and rebound to determine treatment efficacy.  Additionally, this 
technique can also be applied to fertility research such that time to conception is weighted by the 
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probability of initiating fertility treatment.  IPIW allow us to adjust for the effects of many 
different kinds of initiation imbalance in RCTs and can also be used when differences in 
treatment proportions or timing occur simply by chance. 
There were some limitations to this research, mainly that we were unable to completely 
replicate the results from Lee et al. (44) using the publicly available data files (45).  Several 
attempts were made to the lead investigators of the original study, but the programming code 
used to create the variables was not publicly available and could not be shared with us.  
However, the outcomes of interest we found had very similar counts for opioid relapse and 
overdose events compared to Lee et al. (44).  Lee et al. also stated that this study was not 
designed to power differences between the two groups for overdose events.  The X:BOT study 
was designed to power differences for a primary outcome of time to relapse (37), therefore we 
can presume this study was also not powered to detect differences between the two groups for 
positive urine tests.  There was also substantial drop out in the XR-NTX group due to failed 
induction, leading to a reduction in overall study power when analyzing the data using a PP 
approach.  Additionally, the publicly available data files (45) and the outcomes of interest were 
assumed to be true and accurate, despite the inability to fully reproduce the results from Lee et 
al. (44). 
Limitations of using IPIW include the assumption that all confounders are observed when 
creating the weights.  We accounted for several potential confounders in our weights, but this 
does not mean that we have guaranteed this assumption has been met, which could cause 
potential bias on our estimate (53).  Use of IPIW is also limited to studies where the occurrence 
of an event has an assumed profound effect on the outcome; in the X:BOT data, this would be 
induction and relapse, respectively.  In future substance abuse randomized controlled trials, we 
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propose the optimal analysis should include IPIW to address differential induction when 
























A computer simulation was conducted to examine the performance of using inverse 
probability induction weighting in the context of a Cox model for time-to-event data.  This 
simulation was created by replicating the X:BOT trial conditions.  There were n = 570 
observations created for each dataset with a 1:1 treatment distribution (treatmenti).  The data for 
time to relapse, time to censoring, and time to induction were each simulated using a Weibull 
distribution for the event times.  The Weibull distribution was chosen for these time to event data 
due to its flexibility through providing both location and scale parameters, as well as its fit with 
the proportional hazard assumption.   
Below are the time to event models for relapse, induction, and censoring. 
 
Time to relapse: log𝑅! = 216+ 194(𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡!)+ 1.5𝜀!  
 
Time to induction: log 𝐼! = 1.1+ 3.2 𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡! − 0.8 𝑟𝑎𝑐𝑒𝑤! − 0.8 𝑟𝑎𝑐𝑒𝑏!  
+0.4 𝑑𝑟𝑢𝑔! + 0.04(𝑠𝑐𝑎𝑙𝑒!)+ 0.5𝜀! 
 
Time to censoring: log𝐶! = 149+ 179 𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡! + 2.5𝜀!, where 𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡! is a binary 
variable to replicate naltrexone and buprenorphine-naloxone, 𝑟𝑎𝑐𝑒𝑤! indicates a person’s race as 
white, 𝑟𝑎𝑐𝑒𝑏! indicates a person’s race as black, 𝑑𝑟𝑢𝑔! is a binary variable to indicate primary 
opioid used in the seven days before detoxification admission was heroin, 𝑠𝑐𝑎𝑙𝑒! is the Opiate 
Withdrawal Scale from 0 to 10 that described how uncomfortable the patient’s opioid withdrawal 
was such that 0 represented none and 10 represented almost unbearable, and 𝜀! is a random 
disturbance term that has its variance fixed at 1.0. 
The exact equivalence between the log survival model: 
 
 
log𝑇! = 𝛽! + 𝛽!𝑥! + 𝜎𝜀!,     (A.1) 
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(where 𝑇! is the survival time; 𝑥! is a binary treatment variable; and 𝜎 is the “scale” parameter) 
and the log-hazard form of the model: 
 
    log ℎ(𝑡) = 𝛼 log 𝑡 + 𝛽!∗ + 𝛽!∗𝑥!       (A.2) 
 
is the relationship for the Weibull model such that 𝛽!∗ =
!!
!
 and 𝛼 = !
!
− 1. 
The initial step in deriving the coefficients for each of the time to event models shown 
above was through fitting the X:BOT data to a parametric survival distribution function such that 
the response is a linear effect that is composed of the covariates and a random disturbance term, 
𝜀!.  These estimates were then compared to the proportions of the X:BOT relapses, inductions, 
and censoring.  These estimates were then adjusted by increasing or decreasing the “scale” and 
“shape” values by trial and error until they provided results that replicated the X:BOT data 
proportions.  The covariates used in the time to induction model were chosen based from prior 
knowledge of predictors of induction.   
1000 datasets each of size n=570 were created using the following process.  Time to 
relapse (𝑅!), time to censoring (𝐶!), and time to induction (𝐼!) were simulated for all 570 
individuals.  Relapse status and induction status were then determined by the minimum values, 
summarized in Table A.1.  If 𝑅! < (𝐶! and 𝐼!), then relapse occurred and induction did not.  If 𝐶! 
< 𝑅!, then neither relapse nor induction occurred.  If 𝐼! < (𝑅! and 𝐶!) and 𝑅! < 𝐶! then both 





Table A.1. Summary table of relapse, induction, and censoring status for each condition 
Condition Relapse Induction Censoring 
𝑅! < (𝐶! and 𝐼!) X   
𝐼! < (𝑅! and 𝐶!) 
and 𝑅! < 𝐶! 
X X  
𝐼! < (𝑅! and 𝐶!) 
and 𝐶! < 𝑅! 
 X X 
𝐶! < 𝑅!   X 
 
 
The induction weights were then created using logistic regression modeling of the odds 
of remaining not inducted, separately for the numerator and denominator: 
 
  logit 𝑃 𝐼!" = 𝜃 𝑋! ,𝑉!"!! =  𝛾! + 𝛾!(𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡!)+ 𝛾!!𝑉!"!!  (A.3) 
 
The model used to generate the numerator of the induction weights included only time, 
treatment, and the interaction of time and treatment.  The model used to determine the 
denominator of the induction weights included time, treatment, the interaction of time and 
treatment, as well as the covariates race, primary opioid used in the seven days before 
detoxification admission, and categorical Opiate Withdrawal Scale.  These covariates were 
chosen due to prior knowledge of predictors of induction and/or relapse. 
Once the induction weights were created, as described in detail in the dissertation, a 
weighted Cox model was fitted to each of the 1000 datasets to determine an estimate of the 
treatment effect along with its standard error: 
 
𝜆(𝑡𝑖𝑚𝑒; 𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡) = 𝜆! 𝑡𝑖𝑚𝑒! 𝑒𝑥𝑝 𝛽! 𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡!           (A.4) 
 
	 98	




!!!        (A.5) 
 
where 𝛽! is the treatment estimate for the kth simulation (k=1,…,1000), and 𝐿 𝛽!  is the 
weighted partial likelihood for the kth simulation such that 𝑅 𝑡 = {𝑖 ∶ 𝑌! > 𝑡} represents the risk 
set for the group of individuals who are at risk for failure time t; 𝑌! is the failure time for 
individual i; and 𝜔!" is the inverse probability of induction weights for patient i on day j, where 
day 0 is the date of randomization when detoxification begins. 
   
Table A.2. Variables included in the logistic regression models for induction weights and in the 
Cox models for the hazard ratio (HR) as the estimate of the treatment effect 










Cox Model to 
generate HR 
Treatment X X X 
Time X X  
Treatment*Time X X  
Race  X  
Primary opioid used in 7 days 
before detoxification admission 
 X  
Opiate Withdrawal Scale  X  
 
 
The results across all 1000 simulations were averaged to determine the percent of 
treatment estimate bias and standard error bias: 






×100% where 𝛽 was defined from the X:BOT data. 



















  is the 
standard deviation of the treatment estimates and 𝑆𝐸! is the standard error for the kth simulation. 
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A 95% confidence interval for each hazard ratio was also computed for each simulation.  
The 95% confidence interval coverage for the treatment effect was calculated by determining the 
percentage of the simulated confidence intervals that contained exp (𝛽).  Results are shown in 
Table A.3.   
A simulation using the same process described above was also replicated but for a 
doubled sample of 1140, also with a 1:1 treatment allocation (shown in Table A.3).  This larger 
sample size was used for this simulation to assess how increased sample size would affect the 
treatment estimate bias and standard error bias.  Similarly, the simulation was replicated for both 
sample sizes of 570 and 1140 but with unweighted Cox models to compare the induction-
weighted Cox model to these results.  All results are summarized in Table A.3. 
 
Table A.3. Simulation results for the inverse probability of induction weighting (IPIW) and 
unweighted Cox models  
Simulation 
Type 
n Method Treatment 
Estimate Bias 
SE Bias CI coverage 
Sim 1 570 IPIW  1.61% -8.26% 94.1% 
Sim 2 1140 IPIW 1.20% 2.96% 96.0% 
Sim 3 570 Unweighted  -33.23% 1.79% 72.0% 
Sim 4 1140 Unweighted  -32.06% 0.24% 74.2% 
 
 
Table A.3 shows there is a large difference in the bias between the weighted and 
unweighted Cox models favoring the induction weighted model.  As expected, the treatment 
estimate bias and standard error bias were reduced as the sample size increased. Coverage was 
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